Agency of the United States Department of Health and Human Services
POPULARITY
Categories
469 episodes with fda
421 episodes with fda
300 episodes with fda
401 episodes with fda
208 episodes with fda
256 episodes with fda
145 episodes with fda
195 episodes with fda
195 episodes with fda
131 episodes with fda
107 episodes with fda
73 episodes with fda
199 episodes with fda
55 episodes with fda
84 episodes with fda
85 episodes with fda
72 episodes with fda
75 episodes with fda
143 episodes with fda
94 episodes with fda
66 episodes with fda
68 episodes with fda
135 episodes with fda
150 episodes with fda
111 episodes with fda
247 episodes with fda
61 episodes with fda
77 episodes with fda
52 episodes with fda
37 episodes with fda
104 episodes with fda
47 episodes with fda
47 episodes with fda
121 episodes with fda
100 episodes with fda
97 episodes with fda
73 episodes with fda
95 episodes with fda
73 episodes with fda
71 episodes with fda
50 episodes with fda
66 episodes with fda
44 episodes with fda
45 episodes with fda
53 episodes with fda
50 episodes with fda
69 episodes with fda
67 episodes with fda
85 episodes with fda
66 episodes with fda
38 episodes with fda
57 episodes with fda
54 episodes with fda
99 episodes with fda
Full show notes: https://bengreenfieldlife.com/peptides2026 In this episode with Dr. Matt Cook, recorded days after he returned from Washington, D.C., you'll get a breakdown of what just happened to peptides in the United States. You'll hear what the FDA's Pharmacy Compounding Advisory Committee actually voted on, why seven popular peptides were pulled two years ago, which six of the seven were just recommended for the bulk list, which one was left off, and what all of it means for your ability to get peptides legally from a pharmacy instead of the gray market. You'll also get a guided tour of the peptides themselves: BPC-157 for gut and tissue healing, KPV for inflammation, TB-500 for cell migration and wound repair, MOTS-c as an exercise mimetic, Semax for memory and learning, Epitalon for sleep and longevity, and DSIP for sleep. Dr. Cook explains why peptides behave so differently from ordinary drugs, walks through a safety review covering millions of doses, and shows how his company LifeOS pulls your labs, wearables, and genetics into one HIPAA-compliant place. And if you want to keep every peptide straight, Dr. Cook built a peptide cheat sheet covering what each one does, how to dose it, and where to source it. Episode Sponsors: Timeline: Give your cells new life with high-performance products powered by Mitopure, which unlocks a precise dose of the rare Urolithin A molecule to promote healthy aging. Mitopure now starts at $79 when you go to timeline.com/BEN. Xtendlife Prosta Support Advanced: Comprehensive daily prostate support combining clinically studied ingredients like saw palmetto and beta-sitosterol with vitamins, minerals, and botanicals. Visit Xtendlife.com/BensChoice and use code GREENFIELD for 15% off. Fatty15: Fatty15 is on a mission to optimize your C15:0 levels and help you live healthier, longer. Get an additional 15% off their 90-day subscription Starter Kit at fatty15.com/BEN with code BEN. BIOptimizers Magnesium Breakthrough: Seven essential forms of magnesium in one full-spectrum serving to help you relax, unwind, and sleep deeply so you wake up refreshed. Go to bioptimizers.com/ben and use code ben15 for 15% off any order. ULTRA: A clean, nicotine-free, caffeine-free pouch that delivers smooth, sustained energy and focus using clinically backed nootropics and adaptogens, without the jitters or crash. Visit takeultra.com and use code BENGREENFIELD for 15% off.See omnystudio.com/listener for privacy information.
A.M. Edition for Aug. 6. In a departure from recent precedent, President Trump has called Kevin Warsh repeatedly since he was appointed as Fed chairman, including to seek counsel on how AI and the Iran war are affecting the economy. Plus, airlines are pushing back against federal authorities intensifying immigration enforcement at U.S. airports, including near gates and ticket counters. And the Senate confirms Dr. Erica Schwartz as director of the Centers for Disease Control and Prevention, after a bipartisan grilling on how she would navigate vaccine policy under Robert F. Kennedy Jr. Luke Vargas hosts. Sign up for the WSJ's free What's News newsletter. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Can your smartphone become part of your mental health treatment? Prescription digital therapeutics (PDTs) promise to do exactly that — but what are they, and do they actually work? In this episode, host Gabe Howard is joined by ADAA member experts John Torous, MD, MBI, a digital psychiatry expert, and Michelle A. Patriquin, PhD, ABPP, a clinical psychologist, to separate hype from reality. Together, they explain what PDTs are — and aren't — and how mental health apps fit into modern treatment. The conversation explores how apps can help bridge long wait times for therapy; reinforce skills learned in treatment; track mood, sleep, and behavior between appointments; and provide valuable insights that improve conversations with mental health clinicians. Listeners will learn: the difference between FDA-approved mental health apps and standard wellness apps why choosing the "best" mental health app is less important than finding one you'll actually use consistently how to avoid common misconceptions about digital mental health tools and make informed choices If you've ever opened an app store looking for mental health support, this episode will help you separate marketing from evidence so you can make smarter, safer, and more informed decisions about incorporating technology into your mental health care. This episode has been sponsored by the Anxiety and Depression Association of America (ADAA). Our guest, Dr. Michelle Patriquin, is the John S. Dunn Distinguished Professor and Associate Professor in Psychiatry and Behavioral Sciences at McGovern Medical School at UTHealth Houston, and serves as Assistant Dean of Digital Health & Innovation in the UTHealth Houston School of Behavioral Sciences. She is also Co-Director of Research for the John S. Dunn Behavioral Sciences Center, the largest academic inpatient psychiatric hospital in the United States. She is a board-certified clinical psychologist and researcher focused on digital mental health: bringing data-driven, tech-enabled mental health care into real-world clinical setting - especially intensive and inpatient mental healthcare - to improve safety, recovery, and access. Her work is widely published and is supported by state, federal, and foundation funding. Our guest, John Torous, MD, MBI, is director of the digital psychiatry division in the Department of Psychiatry at Beth Israel Deaconess Medical Center (BIDMC), a Harvard Medical School-affiliated teaching hospital, where he also serves as a staff psychiatrist and associate professor. He has a background in electrical engineering and computer sciences and received an undergraduate degree in the field from UC Berkeley before attending medical school at UC San Diego. He completed his psychiatry residency, fellowship in clinical informatics, and master's degree in biomedical informatics at Harvard. Dr. Torous is active in investigating the potential of mobile mental health and AI technologies for psychiatry, and his team supports mindapps.org as the largest database of mental health apps, mindApps.ai for benchmarking AI chatbots, mindLAMP technology platform for scalable digital phenotyping and interventions, and the Digital Navigator program to promote digital equity and access. Dr. Torous has published over 300 peer reviewed articles and 5 book chapters on the topic. He directs the Digital Psychiatry Clinic at BIDMC which seeks to improve access to and quality of mental health care through augmenting treatment with digital innovations. Dr. Torous serves as editor-in-chief for the journal JMIR Mental Health, web editor for JAMA Psychiatry, and a member of various American Psychiatric Association committees.
Women's health has long been underserved by research, leaving many women without the information they need to understand their own bodies. On this week's episode of the WHOOP Podcast, WHOOP Global Head of Human Performance and Principal Scientist Dr. Kristen Holmes sits down with Dr. Elina Berglund Scherwitzl, Co-Founder & CEO of Natural Cycles° and Nobel Prize-winning particle physicist. The conversation explores how data is transforming women's reproductive health.After helping discover the Higgs boson, Dr. Berglund Scherwitzl turned her expertise in physics and data science toward her own health journey by creating the world's first and only FDA-cleared birth control app. Together, Dr. Holmes and Dr. Berglund Scherwitzl discuss how wearable technology and physiological data are giving women unprecedented insight into fertility, pregnancy planning, menstrual health, and perimenopause.The conversation explores the new WHOOP and Natural Cycles° integration, designed to make women's health feel less overwhelming and more intuitive by combining continuous wearable data with advanced insights on fertility, hormonal health, and perimenopause. Dr. Holmes and Dr. Berglund Scherwitzl discuss how body temperature and other biomarkers reveal hormonal changes, why perimenopause often begins earlier than many women realize, and how passive, personalized insights can reduce uncertainty, ease mental load, and empower women to make informed decisions about their health at every stage of life.(00:00) Cold Open (00:37) Meet The Scientist Behind Natural Cycles°(01:00) Why Dr. Berglund Scherwitzl Started Natural Cycles°(04:35) The Only FDA-Cleared Birth Control App(05:54) The WHOOP x Natural Cycles° Partnership(07:51) The Early Signs of Perimenopause (And How To Track Them)(13:08) What Really Happens To Your Hormones Over Time(17:34) Why Understanding Your Body Changes Everything(19:09) Your Sleep Could Reveal Early Signs of Perimenopause(22:03) The Small Habits That Make A Big Difference(24:14) The Most Common Menstrual Cycle Myths(26:09) What Your Wearable Can Tell You About Your Hormones(27:07) The Truth About Fertility Timing(29:16) Knowing Which Symptoms Matter Most(31:36) HRT: What Women Should Know(34:10) What You Can Expect From The WHOOP x Natural Cycles° Partnership(37:05) The Future of Women's HealthFollow Dr. Elina Berglund Scherwitzl:LinkedInWebsiteFollow Natural Cycles°:InstagramYouTubeWebsiteSupport the showFollow WHOOP:Sign up for WHOOP Advanced LabsTrial WHOOP for Freewww.whoop.comInstagramTikTokYouTubeXFacebookLinkedInFollow Will Ahmed:InstagramXLinkedInFollow Kristen Holmes:InstagramLinkedInFollow Emily Capodilupo:LinkedIn
On this episode of Vitality Radio, Jared shares the story behind the long-awaited return of the Ultimate Vitality Multi and explains why this is the most significant reformulation in the product's history. After addressing the unexpected supply delays, he walks through every major upgrade, including the addition of PQQ and CoQ10 for mitochondrial support, clinically relevant lutein and zeaxanthin for eye health, expanded metabolic support with chromium and vanadium, enhanced detoxification ingredients, higher potency adaptogens, and improved nutrient forms throughout the formula. Jared also explains the philosophy behind creating a three-capsule daily multivitamin that prioritizes meaningful ingredient forms and potencies while remaining an exceptional value. If you've ever wondered what separates a premium multivitamin from an ordinary one, this episode is for you. Products:NEW & IMPROVED Ultimate Vitality MultiAdditional Information:655: Behind the Label: What cGMP, NSF & Third-Party Testing Really Tell You346: The Ultimate Vitality Multi - What Makes It the Ultimate Multivitamin for YouVisit the podcast website here: VitalityRadio.comYou can follow @vitalitynutritionbountiful and @vitalityradio on Instagram, or Vitality Radio and Vitality Nutrition on Facebook. Join us also in the Vitality Radio Podcast Listener Community on Facebook. Shop the products that Jared mentions at vitalitynutrition.com. Let us know your thoughts about this episode using the hashtag #vitalityradio and please rate and review us on Apple Podcasts. Thank you!Just a reminder that this podcast is for educational purposes only. The FDA has not evaluated the podcast. The information is not intended to diagnose, treat, cure, or prevent any disease. The advice given is not intended to replace the advice of your medical professional.This podcast is produced by DrTalks.comhttps://drtalks.com/podcast-service/
Send us Fan MailWhat happens when God calls you to leave a comfortable life before showing you exactly where He is leading?In this episode of You Are More, I sit down with David Knapp, creator and host of On the Pen, for an honest conversation about fear, faith, purpose, and trusting God with an uncertain outcome.David's journey began after he was diagnosed with Type 2 diabetes and started taking Mounjaro. Wanting to understand the medication, he immersed himself in scientific literature, FDA documents, and emerging research about GLP-1 medications.When he realized few people were translating that complicated information into language patients could understand, he began sharing what he was learning.At the time, David was selling traffic signals and creating videos wherever he could—including inside his Ford Flex. Today, On the Pen is a top-rated podcast, and David has become one of the country's leading independent voices and patient advocates in the GLP-1 space.But this conversation is about so much more than David's professional success.We talk about the limiting belief that nearly kept him in a comfortable career, the moment he knew it was time to take a leap of faith, and how God used every part of his previous season to prepare him for what came next.David also shares what happened when he unexpectedly needed approximately $40,000 to close on a new studio—just as his largest podcast sponsor backed out. His wife and four children gathered around him to pray, and within 24 hours, every dollar they needed had been provided.This is a powerful reminder that experiencing fear does not mean we lack faith. Fear is an emotion, but cowardice is allowing fear to keep us from doing what God has asked us to do.Your fear may come with you, but it does not get to lead you.If you feel God calling you out of your comfort zone, this conversation will encourage you to remember His past faithfulness, pray bigger, take the next step, and trust Him with the outcome.In this episode, we discuss:• David's journey from Type 2 diabetes to GLP-1 advocacy• How On the Pen became a trusted podcast and platform• Leaving a comfortable career to follow God's calling• The difference between fear and cowardice• Why resistance is not always a sign to stop• Trusting God through financial and business uncertainty• The family prayer that preceded a $40,000 breakthrough• Teaching the next generation to pray big• Remembering God's faithfulness when facing a new giant• Believing that God is truly who He says He is• Using influence and opportunity for Kingdom impactConnect With Us:Website: https://www.youaremore.comJoin The 6AM Club Bible Study! Bible Study: https://www.youaremore.com/bible-study Free Download: 5 Steps to Win Through Adversity https://youaremorepodcast.com/store Social Media: Follow us on Facebook https://www.facebook.com/youaremorepodcast and Instagram https://www.instagram.com/amywienands/ Email: amy@amywienands.comCHAPTERS:00:00 Welcome and Meet David Knapp02:02 Honoring the Legacy of David's Father04:12 David's Type 2 Diabetes Diagnosis07:02 Why He Started Talking About GLP-1 Medications09:22 The Unexpected Growth of On the Pen12:06 Leaving the Comfort of a Successful Career15:10 Trusting God with an Uncertain Outcome18:34 Why God Calls Us Beyond the Familiar21:16 Knowing When It Was Time to Take the Leap24:24 How a Ten-Year Stepping Stone Prepared David27:08 Losing Funding and His Largest Podcast Sponsor30:12 A Family Prayer and a $40,000 Breakthrough33:16 Teaching His Children to Pray Big36:08 Remembering God's Faithfulness39:14 Stepping Out in Fear Instead of Cowardice42:14 Do You Believe God Is Who He Says He Is?45:18 God Created You for a Unique Purpose47:32 Take the Next Step and Watch God MoveIf this conversation encouraged you, subscribe to You Are More, leave a comment, and share it with someone who may be standing at the edge of their next step.Remember: you truly are more.Be intentional, stay focused, and remember you are more!
One of the largest Cyclospora outbreaks in U.S. history has placed fresh produce safety under the national spotlight. In this episode of Inside Food Safety, presented by Testo North America, Carl Fiadini and co-host Eric Moore are joined by nationally recognized produce safety expert Kiley Harper-Larsen, M.S., Owner of The Ag Safety Lady and a food safety executive with more than two decades of experience spanning farms, processing facilities, audits, crisis management and regulatory compliance. She has spent her career working everywhere from farms and packing houses to boardrooms, recalls and FDA inspections. Together, they examine the ongoing Cyclospora outbreak linked to Taylor Farms and discuss what is currently known, what remains unknown, and why outbreaks like this are among the most difficult events for the produce industry to investigate. Topics include: • What Cyclospora is and how it spreads • Why produce outbreaks are uniquely challenging to trace • Farm-to-table food safety systems • Supply chain accountability • Worker hygiene and agricultural water • Consumer risk and practical guidance • The role of technology and testing • What the industry must do to prevent future outbreaks Rather than assigning blame, this conversation explores the science, the systems and the lessons that can help strengthen food safety across the entire supply chain. Guest: Kiley Harper-Larsen, M.S. Owner & Lead Consultant, The Ag Safety Lady Former Corporate Safety Director, A. Duda & Sons Former Vice President of Product & Personnel Safety, J&J Family of Farms Presented by Testo North America
The Gut-Lung Axis: The Missing Link in Chronic Inflammation & Aging | Dr. Vivek Lal Your lungs have a microbiome, and almost no one is talking about it. This episode reveals the hidden pathway behind asthma, chronic inflammation, and slow aging, and gives you a science-backed way to biohack your breath from the inside out. Get A generous discount on Resbiotic by going to: https://resbiotic.com/ and using code ‘DAVE20' Host Dave Asprey sits down with Dr. Vivek Lal, MD, FAAP, a double board-certified physician scientist who discovered the gut-lung axis while running the Pulmonary Microbiome Lab at the University of Alabama at Birmingham. He serves as Director of Clinical Innovation at UAB's Marnix Heersink Institute of Biomedical Innovation and trained in pulmonary and vascular biology at UT Southwestern before completing MIT's executive program in drug and device development. As a serial entrepreneur through his venture studio Biostack Ventures, he founded and now serves as CEO of Resbiotic Nutrition, and also launched Alveolus Bio, an FDA-track pulmonary drug development company. His decade of research turned into the world's first probiotic built specifically for respiratory health. Dave and Vivek break down MMP-9, the overlooked inflammatory pathway that drives collagen breakdown, chronic lung disease, and accelerated aging throughout the body. They cover why germ-free mice outperform normal mice, how antibiotics and toxic mold reshape your lung bacteria for years, why breathwork actually changes your lung microbiome, and how postbiotics and inhaled probiotics could become the next frontier in functional medicine. Along the way they get into supplement formulation, drug development red tape, and why self-experimentation should be treated as a right, not a privilege. You'll Learn: What the gut-lung axis is and how gut bacteria control inflammation in your lungs Why MMP-9 may be the next major longevity pathway after sirtuins How antibiotics, toxic mold, and vaping damage your lung microbiome long term Why breathwork and lung training measurably change your lung bacteria How postbiotics and inhaled probiotics could replace inhalers and steroids Why product-level clinical testing matters more than single-ingredient hype How self-experimentation, AI, and personalized data are reshaping medicine Thank you to our sponsors! - ELITE Performance Coaching | If you'd like to discover where you may be addicted to struggle, allergic to success, and what may be standing between you and your next breakthrough, visit FastestChange.com - ZenBud | Dave's Nervous System Biohack. Visit zenbud.health and use code DAVE15 at checkout for a discount. - Caldera + Lab | Go to calroy.com/dave for the research, a discount, and a 45-day money back guarantee. - Calroy | Go to calroy.com/dave for the research, a discount, and a 45-day money back guarantee. Dave Asprey is a four-time New York Times bestselling author, founder of Bulletproof Coffee, and the father of biohacking. With over 1,000 interviews and 1 million monthly listeners, The Human Upgrade brings you the knowledge to take control of your biology, extend your longevity, and optimize every system in your body and mind. Each episode delivers cutting-edge insights inhealth, performance, neuroscience, supplements, nutrition, biohacking, emotional intelligence, and conscious living. New episodes are released every Tuesday, Thursday, Friday, and Sunday (BONUS). Dave asks the questions no one else will and gives you real tools to become stronger, smarter, and more resilient. Keywords: gut-lung axis, lung microbiome, MMP-9 inflammation pathway, Resbiotic review, does Resbiotic work, Resbiotic lung support, Dr. Vivek Lal, gut-lung axis probiotic, lung microbiome science, MMP-9 longevity pathway, MMP-9 collagen breakdown, best probiotic for lung health, probiotics for asthma, probiotics for allergies, inhaled probiotics FDA, postbiotics for inflammation, NLRP3 inflammasome, NF-kappa B pathway, breathwork lung microbiome, toxic mold lung bacteria, antibiotics lung damage, biohacking respiratory health, lung microbiome 2026, resbiotic.com discount code DAVE20, functional medicine for lungs, quit vaping lung health Resources: • Get a discount on Resbiotic by going to: https://resbiotic.com/ and using code ‘DAVE20' • Get My 2026 Clean Nicotine Roadmap | Enroll for free at https://daveasprey.com/2026-clean-nicotine-roadmap/ • Dave Asprey's Latest News | Go to https://daveasprey.com/ to join Inside Track today. • Danger Coffee: https://dangercoffee.com/discount/dave15? • My Daily Supplements: SuppGrade Labs (15% Off) • Favorite Blue Light Blocking Glasses: TrueDark (15% Off) • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Join My Substack (Live Access To Podcast Recordings): https://substack.daveasprey.com/ • Upgrade Labs: https://upgradelabs.com Timestamps: 00:00 – Cold Open 01:08 – Intro 05:17 – Discovering the Lung Microbiome 16:58 – Antibiotics' Effect on Lungs 20:30 – MMP-9 Explained 25:56 – NLRP3 & the Inflammasome 31:36 – The Right to Self-Experiment 42:04 – Lung Training 1:00:18 – Astronaut Microbiomes 1:12:33 – Closing & Discount Code See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
On this episode of the 40+ Fitness Podcast, Coach Allan breaks down the fight playing out right now in Washington, DC, between GLP-1 medications and peptides. The two keep getting mentioned in the same breath, but they sit on opposite sides of the evidence line. GLP-1s like semaglutide and tirzepatide are tested medications with known dosing and documented side effects. Peptides like BPC-157 and TB-500, the so-called Wolverine stack, are not approved for human use and live in a gray market built mostly on rat studies and anecdote. Coach Allan walks through the recent FDA Pharmacy Compounding Advisory Committee panel that recommended approving 6 of 7 peptides even after the agency's own scientists raised safety concerns, and he points out what it means for you. Time Stamps: 02:54 GLP-1s and peptides, framing the fight 04:26 Peptides and the gray market 05:20 The cheating debate around weight-loss drugs 06:07 The peptides: AOD-9604, BPC-157, TB-500 07:00 Branding and hype: the Wolverine stack 08:50 How both sides market GLP-1s and peptides 09:54 RFK Jr. and what the FDA is for 11:04 Follow the science, not the phrases 12:57 Off-label prescribing and thin peptide data 14:34 Gray market and inconsistent manufacturing 15:47 The FDA compounding panel meets 16:32 FDA scientists warn against approval 17:43 The panel's conflict of interest and 6-of-7 recommendation 19:50 The Joe Rogan ivermectin parallel 22:20 Peptides, cancer risk, and personal caution 23:11 The N=1 experiment and its limits 26:33 Making the decision that's right for you Links - Work with Allan one-on-one (a few coaching slots are open right now): coach@40plusfitness.com - 40+ Fitness: https://40plusfitness.com
On this episode of Diabetes Connections In the news… Sanofi acknowledges an insulin shortage, a new oral therapy for type 1 moves along in research, could there be an actual, accurate, non-invasive CGM in the works, ADA conflict continues and a new documentary about Girl Scout cookies shines a spotlight on T1D. Don't miss our upcoming events! Moms' Night Out in Detroit and Seattle, Club 1921 in Charlotte and Phoenix: https://diabetes-connections.com/events/ Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Transcript: (Stacey Track) On this episode of Diabetes Connections In the news… Sanofi acknowledges an insulin shortage, a new oral therapy for type 1 moves along in research, could there be an actual, accurate, non-invasive CGM in the works, ADA conflict continues and I can't wait to tell you about Cookie Queens.. that's coming up right after this. (AD BREAK) Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bring you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. We are still looking for your community commercials. These are 30–60 second audio spots created by members of the diabetes community to share: Events you're organizing: a fundraiser, walk, or local meetup Products you've created: maybe you've written a book, have a Substack, designed a T1D-friendly gadget, or launched a small business Helpful projects or resources: things you think others in our community should know about It's your chance to share what you're doing and help others get connected! Full instructions are on the website. While you're there please check out our events. We're turning toward fall and we have a lot going on – MNO and Club 1921. Okay.. our top story this week: XX I want to talk about Cookie Queens! It might not sound like a hard news story.. but It's my show and I can't wait to watch this. This move follows four Girl Scouts ages 5-12 during cookie season. One of the girls has type 1 – they don't mention it in the trailer, but you can see her omnipod. Here's a clip: Start the very beginning and stop after "I want to be a supreme court justice." (stop after the "oh..laughter" https://www.youtube.com/watch?v=nnSQS43Eil8 Viewers meet Ara from San Diego, CA (5), Shannon Elizabeth from El Paso, TX (8), Nikki from Chino, CA (9), and Olive from Charlotte, NC (12). Ara has Type 1 diabetes and is shown taking insulin, refilling her pump before bed, and determining with her dad how to sample the cookies she's selling while keeping her blood sugar levels safe. Thumbs down to the Hollywood reporter dot com. In their review they say.. "if this film were itself a baked good, Ara would need to be careful because one bite could cause hyperglycemia or even diabetic ketoacidosis. It's just that sweet." Cookie Queens comes out this month. https://www.hollywoodreporter.com/movies/movie-reviews/cookie-queens-review-prince-harry-meghan-markle-girl-scouts-1236484555/ trailer: XX Supply issues for Lantus SoloStar pens being acknowledged by Sanofi. The company says it's experiencing "a period of intermittent supply due to increased demand. The company said the increase in demand is being driven by "broader market dynamics," but did not provide additional details. Sanofi said the situation is temporary and is expected to improve over the coming weeks. The company said Lantus U-100 vials and Toujeo U-300, which contain the same active ingredient, remain available. https://www.wral.com/news/local/common-insulin-pen-faces-supply-issues-amid-rising-demand-july-23-2026/ XX The University of Alabama at Birmingham startup TIXiMED Inc. has launched the next phase of clinical testing for a novel oral therapy for Type 1. For now called TIX100, a small-molecule drug designed to inhibit a protein linked to pancreatic beta-cell loss and diabetes progression. The new double-blind, randomized, placebo-controlled study will evaluate the drug's safety, tolerability and pharmacokinetics. Researchers will enroll 18 healthy participants across three dose cohorts at a single United States study site. Participants will receive either TIX100 or a placebo twice daily for 28 days, followed by a seven-day follow-up period. Six participants making up the first cohort have been successfully enrolled thus far. In addition to its potential use in Type 1 diabetes, TIX100 may have applications in Type 2 diabetes and obesity. A recent study found that the drug prevented weight regain and preserved lean muscle mass after discontinuation of GLP-1 therapies in preclinical models. https://www.uab.edu/news/research-innovation/startup-advances-novel-oral-type-1-diabetes-therapy-to-next-phase-of-human-testing XX Researchers at the University of California San Diego say they have developed and validated a Continuous Health Analyzing Ring Module (CHARM), a compact, fully integrated wearable smart ring capable of continuous real-time monitoring of multiple biomarkers in sweat. The wearable device can simultaneously measure up to four biomarkers, including glucose, ketone, uric acid, lactate, ascorbic acid, and alcohol, to provide real-time insights into metabolic health. The study is published in Nature Communications. They say CHARM device contains all necessary biomarker sensors, low-power electronics, and a flexible battery. The left compartment of the device is designed to draw sweat passively using an osmotic hydrogel, a soft polymer that creates a pressure gradient to pull fluid from the skin painlessly. The sweat is then analyzed by multiplexed electrochemical sensor arrays within the same compartment, leading to simultaneous and real-time tracking of four biomarkers at a time. The right compartment of the device contains a flexible zinc-silver oxide rechargeable battery that supplies power for up to 12 hours of operation between charges. Biomarker information generated through sensors is wirelessly transferred to a connected Bluetooth-enabled device for real-time display The findings indicated that the device performed well in initial temperature, cytotoxicity, and on-body compatibility tests. It also demonstrated high analytical accuracy in preliminary studies involving healthy participants and individuals with type 1 diabetes, highlighting its potential for non-invasive metabolic monitoring. The calculated estimated sweat-based blood glucose concentration showed a mean absolute relative difference of approximately 13.7% against its corresponding blood concentration values. The device needs further validation in diverse clinical settings and across large diabetic cohorts. https://www.news-medical.net/news/20260727/Prototype-smart-ring-tracks-multiple-sweat-biomarkers.aspx XX Hotter weather and rising temps appear to increase the short term risk for low blood sugar in adults with type 1. An analysis of more than 32 million continuous glucose monitor (CGM) readings from nearly 700 adults with T1D in the UK showed a 26% greater risk for hypoglycemia at a temperature of 25 °C (77 °F) than at 13 °C (55.4 °F). Hypoglycemia was defined as a glucose level < 3.9 mmol/L (70 mg/dL). The study included 679 individuals with T1D and 32,966,282 CGM readings collected between February 23, 2017, and August 8, 2024. Participants had a mean age of 46.4 years and a mean T1D duration of 23.7 years. The researchers observed strong seasonal patterns, with lower odds of hypoglycemia in late winter and early spring, followed by a peak during the summer. The lowest risk occurred on Mondays. The odds then increased over the course of the week and peaked toward the weekend, with a significant odds ratio of 1.14 on Saturdays compared with Mondays. Increases in hypoglycemia were observed during both hot and cold weather, but the association was stronger for heat. The net odds ratio was 1.26 at 25 °C compared with 13 °C. https://www.medscape.com/viewarticle/when-temperatures-climb-hypoglycemia-risk-rises-type-1-2026a1000q4r XX Seven weeks after the expulsion of five diabetes experts from the American Diabetes Association conference, controversy continues. More than 200 members now calling for two ADA leaders to resign. In response, the ADA delivered its own message Tuesday, expressing appreciation for members' patience while a report is prepared. The resignation demand, sent last week in an open letter to the ADA board of directors, calls for the removal of CEO Charles Henderson and chief scientific and medical officer Rita Kalyani. It also urges "an independent investigation into the events of the 2026 Scientific Sessions in New Orleans, a full apology to the five colleagues removed from the meeting, and the restoration of editorial independence at Diabetes Care," an ADA scientific journal. https://www.statnews.com/2026/07/28/american-diabetes-association-fallout-researchers-expulsion/ XX XX Still to come, , a new link between diabetes and dementia, device updates, and why you might want to start rooting for the Red Sox.. XX New study says that people diagnosed with type 1 diabetes (T1D) before the age of 10 years had a 37% higher risk of developing all-cause dementia later in life than those diagnosed between ages of 18 and 30 years. These researchers used a Swedish national register of 43,440 individuals with T1D (mean age at cohort entry, 33 years; 44% women) Worth noting a couple of things.. the mean age in this study was 33 – so the people who were diagnosed under the age of ten would not have had access to current technology – no CGMs or AID systems. And while the study says it's 37% higher for the younger group, the actual rate was still very low. As always, I'll link to the study so you can learn more. My obvious bias here to look for a silver lining because I have a son who diagnosed with T1D at age 2. https://www.medscape.com/viewarticle/type-1-diabetes-onset-before-age-10-tied-higher-risk-2026a1000pir XX Researchers have developed a machine learning model that uses routine clinical information to detect diabetes and distinguish between type 1, type 2, prediabetes, and diabetes caused by pancreatic disease. The model performed well in early testing, but researchers say it still needs to be validated in independent patient groups before it could be considered for use in diabetes screening or clinical care. It did not assess clinical utility, patient outcomes, or quality of life. https://www.news-medical.net/news/20260729/Researchers-train-AI-to-detect-diabetes-and-assign-four-diagnostic-labels.aspx XX Trinity Biotech and Latch Medical are teaming up to explore combining CGM with precision drug delivery technology for diabetes, obesity, and other metabolic conditions. The companies hope real-time glucose data from Trinity's CGM+ sensor could eventually help guide more personalized treatment decisions and medication delivery. Trinity's CGM+ is still in development, with a pivotal clinical trial planned for later this year. https://www.drugdeliverybusiness.com/trinity-biotech-collab-cgm-drug-delivery/ XX The FDA selects Dexcom as the first participant in a new digital health pilot that will exempt certain digital health devices from FDA premarket authorization requirements while collecting real world data through a complementary Medicare program. Dexcom, plans to implement an artificial intelligence-enabled glucose health program through the pilot. The program is intended to help screen for prediabetes and Type 2 diabetes. The company plans to integrate data from its sensors, including its prescription G7 CGM and its over-the-counter Stelo device, along with contextual health information such as nutrition, physical activity, sleep and stress. The FDA announced plans for the Technology-Enabled Meaningful Patient Outcomes, or TEMPO, pilot last year amid a broader push for adoption of digital health and wearables. It coincides with a new program by the CMS to fund the use of digital technologies for managing chronic conditions. https://www.healthcaredive.com/news/fda-names-dexcom-as-first-participant-in-digital-health-pilot/826215/ XX Medicare and Medicare Advantage beneficiaries now have access to the new MiniMed Flex insulin pump. Beneficiaries can now access the MiniMed Flex and its latest sensor portfolio, which currently includes the Simplera Sync sensor, a disposable, all-in-one sensor with easy two-step insertion. The company plans to roll it out with the Instinct sensor, made by Abbott, later this summer. It also added Abbott's dual glucose-ketone sensor (still investigational in the U.S.) to its portfolio this year. Flex picked up FDA clearance in March and the company announced the initial commercial rollout of the pump last month. https://www.drugdeliverybusiness.com/minimed-flex-pump-now-available-medicare/ XX Eli Lilly expands it's partnership with Resilience – the makers of the KwikPen device. Through the investment, Resilience will significantly increase U.S. production of Lilly's KwikPen injectable device for diabetes and obesity medicines. In February, Lilly won FDA approval for Zepbound in a multidose KwikPen device. The product includes four doses of the GLP-1/GIP receptor agonist, providing a month of treatment for obesity or overweight in one device. Resilience expects the KwikPen capacity expansion to create at least 400 jobs in the Cincinnati area. https://www.biospace.com/deals/lilly-and-resilience-invest-750m-in-diabetes-and-obesity-drug-device-supply XX Alex Cooper – the host of the top podcast Call her Daddy – announced she's been diagnosed with gestational diabetes. "When I got this diagnosis, the first couple days, I was really hard on myself," the 31-year-old admitted. "It felt very isolating, like, as much as my family and my husband and everyone was there for me I just felt like, it's me on an island." She says she found an online community that's been helping. In sharing her experience, she hoped it would alleviate the stress. https://www.eonline.com/news/1434556/pregnant-alex-cooper-shares-isolating-gestational-diabetes-diagnosis XX Several amazing diabetes non profits are vying for big charity dollars from the Boston Red Sox. The IMPACT Awards provide Red Sox fans with the chance to nominate their favorite, most impactful nonprofit organization serving New England for their opportunity to win a grant from the Red Sox Foundation. In 2026, the IMPACT Awards will focus on organizations that are supporting research and providing awareness, advocacy, and services to people with diabetes. Check out all the charities and vote for your favorites – you've heard of so many of these I promise – at the link in the episode show notes, . https://www.mlb.com/redsox/community/red-sox-foundation/impact-awards?partnerId=redirect-bos-impact
Cyclospora is a microscopic organism that is causing a big problem in the U.S.Cases of cyclosporiasis have been growing throughout the summer, with about 4,000 reported cases in Ohio alone.Federal health officials are still investigating the source. How much longer do we have to worry about the produce we eat? Have recent cuts to federal agencies played a role in the outbreak?This episode of All Sides will discuss the public health outbreak with a public health expert, gastroenterologist and journalist who covers the CDC and FDA.Guests:Sanja Ilic, food safety state specialist/professor of human nutrition, Ohio State UniversityDr. We'am Hussain, gastroenterologist, Kettering HealthMarcia Brown, food and agriculture reporter, POLITICOphoto: Jeff Amy / AP
Novo Nordisk has spent years warning patients, regulators, lawmakers, and courts about the risks of synthetic semaglutide. Now, as patents begin to expire and China's pharmaceutical industry becomes increasingly important, Novo may be staring at a very uncomfortable question: what happens if synthetic semaglutide suddenly makes sense when Novo is the one making it?In this week's episode of The Weekly Dose, I dig into Novo's long-running recombinant-versus-synthetic semaglutide argument, the lawsuits and FDA petitions built around it, and a clip from more than 16 months ago showing that we were covering this exact issue long before it became part of the mainstream conversation. Novo Warned Us About Synthetic Semaglutide_ Now This_.txtWe also break down Pfizer's decision to kill two clinical-stage obesity drugs, including an oral GLP-1 acquired through its $10 billion Metsera deal, the strange science behind GIP receptor antagonism, and why Pfizer's remaining obesity pipeline still deserves attention. Plus, Wall Street is looking at Eli Lilly's obesity-fueled rally and asking just how big this market can get.In this episode:00:00 Novo's synthetic semaglutide problem02:00 VoaFit sponsor message03:30 The 16-month-old On The Pen receipt05:00 Recombinant vs. synthetic semaglutide07:00 Novo's FDA, legal, and political strategy09:00 Pfizer kills two obesity drugs11:00 What happened to Metsera's oral pipeline?13:00 The GIP agonist vs. antagonist paradox15:00 Why China matters to Pfizer and Novo17:00 Could Novo eventually make synthetic semaglutide?18:30 What comes next for Lilly, Novo, and PfizerThe big question: If Novo Nordisk eventually launches its own synthetically manufactured semaglutide, does that change how you view the arguments it has made against compounded semaglutide over the last several years?Comment below. I want to know where you land.More obesity medicine news and analysis: OnThePen.comAll my links, socials, and resources: linktr.ee/manonthemounjaroThis episode is sponsored by VoaFit. Learn more at voafit.com/otp.#GLP1 #Semaglutide #Ozempic #Wegovy #NovoNordisk #CompoundedSemaglutide #ObesityMedicine #Pfizer #EliLilly #Mounjaro #Zepbound #Metsera
View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter Jim Otvos is a biophysical chemist who pioneered the use of nuclear magnetic resonance (NMR) spectroscopy to measure lipoprotein particles and developed the first FDA-cleared method for directly quantifying LDL particle number (LDL-P), a technology that has since expanded to provide broader insights into metabolic health, inflammation, insulin resistance, and mortality risk. In this episode, Jim recounts the unlikely story of transforming a flawed cancer test into a new way of measuring lipoproteins, explains what standard cholesterol tests can miss and why LDL-P and apoB can inform treatment decisions beyond LDL cholesterol alone, and dispels the misconception that large, "fluffy" LDL particles are benign. He also explores how NMR can reveal insulin resistance before blood sugar rises, GlycA as a marker of chronic low-grade inflammation, and the metabolic vulnerability index (MVX) as a potential measure of frailty, resilience, and mortality risk across the lifespan. Finally, Jim explains why NMR diagnostics remain underused despite the wealth of information they can extract from a single blood test. We discuss: How investigating a flawed 1986 cancer test led to the development of NMR (nuclear magnetic resonance) lipoprotein testing [3:30]; How standard lipid panels measure cholesterol and triglycerides, and why LDL cholesterol is estimated rather than directly measured [15:15]; How NMR spectroscopy measures lipoprotein particle size and concentration [20:30]; Why LDL particle number matters more than particle size, and why large, "fluffy" LDL is not benign [28:45]; Discordance between LDL cholesterol and LDL particle number: which measure better reflects cardiovascular risk? [36:30]; How metabolic syndrome and lipid-lowering treatment contribute to the discordance between LDL-C and LDL-P, and the value of particle number for managing risk [45:30]; Using the NMR-derived LP-IR score to detect insulin resistance and predict type 2 diabetes before glucose rises [51:15]; The development, commercialization, and uncertain future of the Vantera NMR Analyzer and NMR-based diagnostics [1:04:45]; The analytical efficiency of NMR testing and the data-driven development of the Metabolic Vulnerability Index (MVX) [1:16:00]; GlycA as an NMR-derived marker of systemic inflammation: its discovery, biological basis, and advantages over hs-CRP [1:25:45]; Developing the Metabolic Vulnerability Index (MVX): biomarkers of inflammation, malnutrition, muscle wasting, and mortality risk [1:34:00]; What MVX can tell us about longevity and mortality [1:44:15]; How MVX may reveal metabolic frailty and predict premature mortality decades in advance in young, healthy adults [1:50:30]; Potential applications of MVX for predicting treatment response, surgical resilience, and clinical trial outcomes, and the barriers to broader use [2:00:00]; ApoB versus LDL-P: their clinical similarities, the additional information provided by NMR, and barriers to broader adoption [2:07:30]; Interpreting the effects of the CETP inhibitor, obicetrapib, on LDL-P, apoB, and small HDL particles [2:13:00]; The future of NMR diagnostics and MVX: translating scientific potential into broader clinical use [2:20:45]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube
While Republicans outrage-monger over Fauci, the Trump administration is quietly continuing many of the same vaccine policies. I'm joined by civil rights attorney and medical freedom hero Aaron Siri to expose why medical freedom advocates are increasingly alarmed by the Trump administration's legal and policy decisions. Siri explains why the Department of Justice is still defending Biden-era vaccine policies in court, why vaccine mandates continue across much of America, and why meaningful reform has largely stalled despite the best efforts of Secretary Kennedy. The discussion also examines the nomination of a CDC director with a history of supporting vaccine mandates, ongoing lawsuits over religious exemptions, transparency battles involving the FDA, and why many Americans continue to face pressure from schools, employers, and health-care providers. One of the most compelling segments focuses on the Amish community in New York, where legal battles over vaccine mandates have raised broader questions about religious liberty, informed consent, and medical freedom. Siri discusses observations presented in court regarding health outcomes within Amish communities and why these cases have become central to the national debate. Learn more about your ad choices. Visit megaphone.fm/adchoices
Today's episode is another in our podcast series featuring companies I genuinely feel aligned with. Today, I'm delighted to welcome Lucy Goff, the founder of Lyma, a pioneering wellness brand transforming beauty and health through science-backed innovation. Before launching Lyma, Lucy built a successful career as a journalist and luxury-sector publicist, during which she honed her expertise in brand storytelling and consumer engagement. I've been using the Lyma laser for several months now, and I've noticed significant improvements in my neck, jawline, and even my knees. Today's conversation centers around Lucy's near-death experience and the origins of Lyma. We explore the differences between cold and hot laser technology, the influence of sirtuins and longevity pathways, what constitutes a clinical-grade device, and the FDA approval process. Lucy explains how skin ages differently during perimenopause and menopause, why the Lyma laser is safe for all skin types, and how it requires no protective goggles and is completely pain-free. We also discuss gut health, HRT, and hormones, the influence of IDO2, and the role of probiotic fibers. Lucy highlights how simplifying can enhance your health in midlife, how using GLP-1 drugs can lead to weight loss and reduce skin laxity, and how the Lyma device can help improve skin quality. I know you will enjoy today's enlightening discussion with Lucy Goff as much as I did while recording it. IN THIS EPISODE, YOU WILL LEARN: How Lucy's near-death experience led to the creation of Lyma How cold laser technology differs from heat-based skin treatments Why LED, red light therapy, and laser technology should not be grouped, and how LED and laser differ in their biological effects and gene expression Lucy explains the extensive testing required for FDA clearance How women's skin changes during perimenopause and menopause The role of the gut microbiome during perimenopause and menopause What inspired the development of Lyma's IDO2 formulation Why Lucy encourages a simpler approach to supporting your health in midlife How the Lyma laser can help improve skin laxity following rapid weight loss with GLP-1 medications Connect with Cynthia Thurlow Follow on X, Instagram & LinkedIn Check out Cynthia's website. Submit your questions to support@cynthiathurlow.com Join other like-minded women in a supportive, nurturing community: The Midlife Pause/Cynthia Thurlow. Purchase Cynthia's book, The Menopause Gut. Cynthia's Intermittent Fasting Transformation Book The Midlife Pause Supplement Line Connect with Lucy Goff Lyma - Use the code CYNTHIA 10 for a 10% discount on the Lyma device and products on the Lyma website
About this episode: In June, the FDA convened an advisory committee to discuss whether seven selected peptides should be permitted for legal sale under pharmacy compounding laws despite little research into safety and efficacy. Agency scientists oppose the decision while some committee members with ties to the growing industry support it. In this episode: Dr. Josh Sharfstein, who previously served as the Principal Deputy Commissioner of the FDA, explains what is happening and what it may mean for consumers and patients. Guest: Dr. Josh Sharfstein is distinguished professor of the practice in Health Policy and Management, a pediatrician, and former secretary of Maryland's Health Department. He served as the Baltimore City Commissioner of Health from 2005 to 2009. Host: Lindsay Smith Rogers, MA, is the producer of the Public Health On Call podcast, an editor for Expert Insights, and the director of content strategy for the Johns Hopkins Bloomberg School of Public Health. Show links and related content: FDA committee votes to make peptides more widely available—Science July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee—FDA Why Are People Injecting Themselves with Peptides?—The New Yorker Peptide boom has states scrambling to protect consumers, Post investigation finds—Washington Post How to Spot Unregulated Pharmacies and Falsified Medications—Public Health On Call (August 2025) Transcript information: Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel. Contact us: Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website. Follow us: @PublicHealthPod on Bluesky @PublicHealthPod on Instagram @JohnsHopkinsSPH on Facebook @PublicHealthOnCall on YouTube Here's our RSS feed Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University.
This month is about the gap between what a system offers and what people actually get from it: drugs that work better with support nobody's paying for, AI that's already answering more medical questions than most doctors ever will, and a labor market where staying healthy can mean staying stuck. Halle and Michael break down the stories reshaping digital health in August.We cover:Why GLP-1 funding is shifting from prescribing platforms into "companion" ecosystemsThe FDA panel vote that opens a legal pathway for six unapproved peptides, and what this could meanOur thoughts on OpenAI's new ChatGPT Health product, now available to every US adultThe Florida pastor's lawsuit against OpenAIWhy nearly one in four US workers are staying in jobs they'd rather leave, just to keep their health insuranceThe healthcare argument buried inside the bill to make daylight saving time permanentLinks:Rock Health, H1 2026 digital health funding recapHalle's research piece, Virtual GLP-1 startups: Pill mills or the future of obesity care?RAPS, FDA advisory committee backs six peptides for compounding listTechCrunch, OpenAI makes ChatGPT Health available to all US usersCBS News, ChatGPT's medical advice nearly killed a Florida man, lawsuit claimsGallup, One in four US employees locked in jobs for health insuranceThe Hill, House passes Sunshine Protection Act—
In this two-guest episode, Howard Farran brings together two very different but complementary paths in reconstructive surgery. Nancy Hairston is the founder and CEO of MedCAD, a Dallas-based medical technology company specializing in patient-matched cranial, facial, and mandibular implants. A sculptor by training — with a fine arts degree and an early career designing toys for Mattel and Disney and building 3D animation software that became Maya — Nancy channeled her mastery of digital sculpting into medicine, earning FDA clearance for her AccuShape cranial implant in 2011 and delivering custom, patient-specific solutions for more than 8,000 individuals since. Dr. Samir Singh is a board-certified oral and maxillofacial surgeon and Fellow of the American College of Surgeons, trained at VCU in complex implant surgery, bone grafting, orthognathic surgery, and maxillofacial trauma, who now practices in North Pittsburgh, teaches and mentors residents, and lectures nationally on full-arch implant reconstruction. Together, the conversation walks through how custom implant design and surgical expertise intersect — the MedCAD process of turning precise imaging into a planned, in-house-manufactured implant delivered to surgical teams around the world, and how that planning removes friction, shortens procedure time, and boosts a surgeon's confidence before the first incision. Dr. Singh shares his journey from Pittsburgh to the operating room, the growth and technology behind his practice, and memorable orthognathic and reconstruction cases, along with his heart for mission work — including trips to treat children with cleft lip and palate in Peru. The episode closes on mentorship and the shadowing and hiring opportunities both guests see for the next generation of surgeons and innovators. Episode #1722 : Dentistry Uncensored with Howard Farran, Howard sits down with two guests at the cutting edge of surgical reconstruction: Nancy Hairston, founder & CEO of MedCAD, and Dr. Samir Singh, board-certified oral and maxillofacial surgeon. From an artist-turned-medical-tech founder who's created patient-matched implants for 8,000+ people, to a surgeon rebuilding faces and jaws with full-arch and orthognathic expertise — this is a fascinating look at how custom design and surgical skill come together in the OR.
In part 2 of his new series, Finding a Solution to the Federal Hemp Ban, Jonathan Miller interviews Christopher Lackner, Founder and President of the Hemp Beverage Alliance. If you have questions about the episode or ideas for Hemp related topics, email us at hemplegallyspeaking@fbtlaw.com. Hemp Industry questions covered in the episode: What is the Hemp Beverage Alliance and what is its mission?What the current marketplace for hemp beverages?What kind of regulation would you like for the hemp beverage industry, and how closely do that compare to alcohol?Should there be THC milligram limits on hemp beverages and if so, what would they be?What is your organization doing to prevent the hemp ban from taking effect? Which legislation do you support?What can our listeners do to join in these efforts?
Richard Lewis turned Tenet off three times. On the fourth attempt he finally made it to the end, and he came out calling it an unfairly maligned film. That is the story of this episode. Thorin picked Tenet expecting a bloodbath, hoping to be the lone defender of Christopher Nolan's most divisive movie. Instead Richard converted, MonteCristo landed somewhere in the middle, and the argument turned into something more interesting: is a film allowed to be incomplete after one viewing? Thorin's position is that Tenet is the only movie ever made that genuinely requires a second watch, because the first time through you are only seeing one side of a temporal pincer movement. Huel: Limited Time Offer – Make healthy eating simple. Get Huel today with our exclusive offer of 15% OFF online with our code LFN at huel.com/LFN. New Customers Only. Thank you to Huel for partnering and supporting our show! Hims: Access to FDA approved GLP-1 weight loss treatments online, with no insurance needed. Get a personalized plan at https://hims.com/fourplay ZenAI: The home of vibe casting. Turn a conversation into a finished podcast or clip with an AI producer. Join the waitlist at bit.ly/zenAI_bpp_horsemen Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Joanna Nathan, CEO and co-founder of Prana Surgical, adjunct professor at Rice University and a former MedTech investor who spent years at the J&J MedTech Center for Device Innovation before crossing over into building herself. Her company recently secured FDA clearance for the Prana System, a tissue-sparing platform rethinking how early stage lung cancer is diagnosed and treated.In this episode, Joanna shares the deeply personal story behind her move from investing back into operating, having lost her four year old son in 2021 and wanting proximity to patient impact rather than evaluating innovation from the sidelines. It is an honest and moving conversation about what actually drives someone to take on a decade-long mission.We get into what she learned watching hundreds of pitches from the investor seat, why a no is very often about portfolio construction and timing rather than the quality of your idea, and why a fundraising pitch is a vision document backed by evidence rather than a journal article. Joanna then breaks down the problem Prana is solving, why removing large portions of lung for a tiny early stage nodule is no longer justifiable and how the system is right-sized for the level of risk these smaller lesions present.We also explore the changing face of lung cancer, the rise of never smokers now approaching one in three patients, why the disease is getting younger and more female, the role of mobile screening in rural areas and where AI genuinely helps rather than replaces clinical judgement. Joanna closes with hard-won advice for anyone thinking about founding a company and why community is what carries you through.Timestamps[00:01:38] From Research to Investing to Building: The Path Back to Operating[00:03:33] Why a No From an Investor Is Rarely About Your Idea[00:05:29] Why a Pitch Is a Vision Document Not a Journal Article[00:07:16] The Problem With Early Stage Lung Cancer Surgery Today[00:09:22] The Rise of Never Smokers and a Disease That Is Changing Fast[00:11:03] Why Women Under 50 Now Face Higher Lung Cancer Rates[00:13:18] Getting Creative on Access: Mobile CT Screening in Rural Areas[00:17:21] AI in MedTech: Assisting Clinical Judgement Not Replacing It[00:19:22] How Houston Became an Unlikely MedTech Powerhouse[00:24:06] Who Should Not Become a Founder and the Decade-Long QuestionConnect with Joanna - linkedin.com/in/joannacnathan/Learn more about Prana Surgical - https://www.pranasurgical.com/Get in touch with Karandeep Badwal - https://www.linkedin.com/in/karandeepbadwal/ Follow Karandeep on YouTube - https://www.youtube.com/@KarandeepBadwalMedical device training courses delivered by Karandeep through Bywater - https://www.bywater.co.uk/
In this episode of the Cannabis Accounting Podcast, Andrew Hunzicker, founder of DOPE CFO, recaps the biggest cannabis industry news from July 2026.Listen to learn about:✅ Medical cannabis permanently moved to Schedule III by the DOJ and DEA in April — why Andrew calls it the biggest cannabis news of the century, and why most people missed what it actually means✅ 280E no longer applies to medical cannabis operators — what a 25% improvement in cash flow and bottom line means for operators, investors, and lenders right now✅ The ALJ hearing on full recreational rescheduling just wrapped — why the anti-cannabis groups' own witnesses admitted cannabis meets the Schedule III definition, and what to expect from closing arguments on August 17th✅ Why two administrations, four federal agencies (HHS, FDA, DEA, DOJ), and 93% of 50,000 public comments make the anti-rescheduling lawsuits a losing battle✅ The MORE Act back in Congress — what full descheduling looks like and why cannabis treated like alcohol is closer than most people think✅ 85% of healthcare professionals already recommending cannabis, teen use down nearly 50% after legalization, and $28 billion in state tax revenue — why holdout states are running out of reasonsArticles mentioned in this episode:https://www.cannabisbusinesstimes.com/cannabis-rescheduling/news/15828911/dea-comes-out-swinging-in-cannabis-rescheduling-hearing https://www.marijuanamoment.net/inside-the-deas-marijuana-rescheduling-hearing-what-i-saw-who-was-missing-and-why-it-matters-op-ed https://norml.org/news/2026/07/02/report-adult-use-cannabis-markets-have-generated-over-28-billion-in-state-tax-revenue https://thehill.com/opinion/healthcare/5954552-controlled-substances-act-marijuana https://themarijuanaherald.com/2026/07/the-history-of-cannabis-legalization-in-the-united-states https://ganjapreneur.com/85-of-u-s-healthcare-professionals-believe-cannabis-has-medical-utility https://ganjapreneur.com/kansas-governor-candidate-pushes-cannabis-legalization-platform https://www.youtube.com/watch?v=9oZL8VjdDkw https://themarijuanaherald.com/2026/07/dea-judge-sets-august-17-deadline-for-final-briefs-following-conclusion-of-federal-marijuana-rescheduling-hearing https://moritzlaw.osu.edu/faculty-and-research/drug-enforcement-and-policy-center/research-and-grants/policy-and-data-analyses/federal-marijuana-reschedulinghttps://thepulse.hollandhart.com/post/102ncn4/schrodingers-schedule-how-the-feds-made-the-cannabis-plant-both-illegal-and-not https://ganjapreneur.com/teen-cannabis-use-dropped-by-more-than-60-in-minnesota-after-legalization https://themarijuanaherald.com/2026/07/glass-house-brands-hires-former-dea-official-to-advise-on-potential-interstate-marijuana-commerce-and-exports
Dr. Brian King — the former director of the FDA's Center for Tobacco Products, who was placed on administrative leave in April 2025 as part of the mass HHS layoffs joins the Chuck Toddcast to explain what happens to public health when the agency charged with protecting it gets deliberately dismantled. King walks through the extraordinary progress America made reducing cigarette smoking over decades, and how quickly that's being unwound: the tobacco industry donated millions to Trump's PAC, executives pressured the White House directly, and the payoff has been regulatory capture and mounting pressure on the FDA to bring flavored products back to market. He's clear-eyed rather than absolutist on the science — combustible products are far and away the most harmful, nicotine itself is highly addictive but isn't what's killing people, though it's genuinely not risk-free for the adolescent brain — and he walks Chuck through the comparison to caffeine, the data on whether vaping serves as a gateway back into smoking, and what's actually known about nicotine pouches, where youth usage isn't high but stubbornly isn't declining either. The industry, meanwhile, is spending roughly a million dollars an hour advertising its products while fighting every government action to reduce smoking. The conversation turns to what actually works and what's being abandoned. King argues the two most effective interventions available are reducing nicotine levels in cigarettes and banning menthol, credits Congress for getting the Tobacco Control Act right, and stresses that Congress — not the FDA acting alone — has to be the one to regulate tobacco, which is precisely why sidelining the agency is so damaging. He and Chuck get into the questions nobody in Washington wants to answer: why are cigarettes legal at all, how are sugary alcoholic beverages not treated in the same category, and where did the money from the 1998 master settlement actually go. King is pointed that the MAHA movement, for all its rhetoric about chronic disease, has done nothing prominent on tobacco, and that the FDA is now actively undermining both the science and the law it was built to enforce. His closing warning is the bleakest note of the episode: America is in a public health apocalypse that will take decades to repair, it will be enormously hard to recruit a next generation into the field, the entire world will be harmed by the collapse of American public health infrastructure — and the impacts are only just beginning to show up. Play ball and swing for the fences on FanDuel, an official partner of the MLB at https://FANDUEL.COM. Protect your family with life insurance from Ethos. Get up to $3 million in coverage in as little as 10 minutes at https://ethos.com/chuck. Application times may vary. Rates may vary. For free and unbiased Medicare help, dial (980) 734-3985 to speak with my trusted partner, Chapter, or go to askchapter.org/chuck /*Paid Partnership Chapter and its affiliates are not connected with or endorsed by any government entity or the federal Medicare program. Chapter Advisory, LLC represents Medicare Advantage HMO, PPO, and PFFS organizations and stand alone prescription drug plans that have a Medicare contract. Enrollment depends on the plan’s contract renewal. While we have a database of every Medicare plan nationwide and can help you to search among all plans, we have contracts with many but not all plans. As a result, we do not offer every plan available in your area. Currently we represent 50 organizations which offer 18,160 products nationwide. We search and recommend all plans, even those we don’t directly offer. You can contact a licensed Chapter agent to find out the number of products available in your specific area. Please contact Medicare.gov, 1-800-Medicare, or your local State Health Insurance Program (SHIP) to get information on all of your options. Timeline: (Timestamps may vary based on advertisements) 00:00 Brian King (FDA center on tobacco) joins the Chuck ToddCast 03:45 We made incredible progress reducing cigarette smoking 04:15 Tobacco companies donated and received regulatory capture 05:00 Flavored vapes appeal more to kids & are problematic 06:30 Trump was pressured by executives from tobacco industry 07:15 There were multimillion dollar donations to Trump’s PAC 08:45 What’s the actual health data on nicotine outside of smoking? 09:15 Combustible products are the most harmful 09:45 Nicotine is highly addictive but isn’t causing the harm and deaths 10:30 Nicotine can harm the adolescent brain, it’s not risk free 11:15 Comparing nicotine vs. caffeine 13:00 Vaping typically isn’t a gateway back into smoking 14:15 There’s been pressure on FDA to bring back flavored products 16:45 $1M dollars an hour is being spent advertising tobacco products 17:30 Industry has been fighting all government action to reduce smoking 19:00 The FDA has been sidelined in the fight against smoking 19:30 Why are cigarettes even legal at all? 21:00 Tobacco farmers have transitioned to other crops in other countries 23:00 Reducing nicotine levels is highly effective 23:30 Outlawing menthol is also highly effective 25:15 Congress got it right with the Tobacco Control Act 27:00 How are sugary alcoholic beverages not in the same category? 28:00 What is age gating technology and how does it work? 30:00 Do we have good data on usage for people under 18? 32:30 Nicotine pouch usage isn’t high amongst kids, but isn’t going down 33:00 What is the data about health impacts from pouches? 34:30 Nicotine has a strong stimulant effect, helps with attention 35:15 Settlement in ‘98 required tobacco companies to pay costs in perpetuity 35:45 States have diverted those funds to other purposes 36:45 Did the tobacco industry actually take a hit from the settlement? 37:30 If still at FDA, what changes would you implement? 38:00 FDA has been undermining the science and the law 39:00 Effectiveness of banning indoor smoking 40:15 Should preventing underage addictions be the north star? 42:30 Congress has to regulate tobacco, FDA can’t do it on its own 43:15 MAHA hasn’t done anything prominent on tobacco 45:30 Is there litigation that could be pursued here? 46:45 We’re in a public health apocalypse, will take decades to repair 47:30 It will be hard to recruit people into public health 49:15 The entire world will be harmed by collapse of American public health 51:00 The impacts are just beginning to show up, will get worseSee omnystudio.com/listener for privacy information.
Chuck Todd opens with the Iran war's arrival on American soil: hackers have hit water systems across multiple states in one of the most serious cyberattacks on U.S. water infrastructure in years and investigators probing an Iranian link. Trump's response tells you everything about the presidency in its current state — he didn't blame the attacker, he blamed the victim, using the hack as an occasion to attack Minnesota Democrats. Chuck’s question hangs over the whole segment: was Trump briefed on the Iranian connection and went after Minnesota anyway? Either way, the first instinct was to find a Democrat to blame, which Chuck calls a kind of polarization disease that leaves a president caring more about his narrative than about American citizens drinking the water. It fits a pattern the episode keeps circling: Jeanine Pirro presented false evidence to a grand jury blaming a former Olympian for damage to the White House reflecting pool, dropped the case when Interior produced documents proving otherwise, and Trump publicly disagreed with dropping it because he still insists it was vandals. Chuck argues negative information never reaches Trump, and people who bring him bad news don't last long — which is how you end up with a president insisting affordability is a Democratic scam Then, Chuck highlights a Wall Street Journal piece that lays out Trump's corruption — roughly $800 million raised through what amounts to an advertised pay-to-play scheme. Anti-corruption is a devastating midterm message sitting right there for Democrats to pick up… then Chuck Schumer rolled out a bill that Chuck calls a piece of garbage: it wouldn't even cover the conduct in the WSJ story, it's likely unconstitutional because it names individuals, and — most absurdly — it creates a new anti-corruption agency inside the executive branch, meaning a corrupt president would appoint its director and seven board members and, per the Supreme Court, could fire them at will. Congress can already do every bit of the oversight the agency would perform and Schumer's answer to executive corruption is to hand the executive more power and write Congress out of its own job. He closes on Michigan and Wisconsin as the clearest signals of where the Democratic Party is headed — Abdul El-Sayed running a movement inside a Senate race with the explicit goal of changing the party, DSA-endorsed Francesca Wong leading in Wisconsin while the establishment fails to coordinate against her — and on the DSA's new call to abolish the Senate, which Senate Democrats pushed back on without ever defending the institution. Chuck defends it himself: the Senate is a feature, not a bug, a brake on political extremism, and the right response to losing an argument is to win it rather than rewrite the rules. Then, Dr. Brian King — the former director of the FDA's Center for Tobacco Products, who was placed on administrative leave in April 2025 as part of the mass HHS layoffs joins the Chuck Toddcast to explain what happens to public health when the agency charged with protecting it gets deliberately dismantled. King walks through the extraordinary progress America made reducing cigarette smoking over decades, and how quickly that's being unwound: the tobacco industry donated millions to Trump's PAC, executives pressured the White House directly, and the payoff has been regulatory capture and mounting pressure on the FDA to bring flavored products back to market. He's clear-eyed rather than absolutist on the science — combustible products are far and away the most harmful, nicotine itself is highly addictive but isn't what's killing people, though it's genuinely not risk-free for the adolescent brain — and he walks Chuck through the comparison to caffeine, the data on whether vaping serves as a gateway back into smoking, and what's actually known about nicotine pouches, where youth usage isn't high but stubbornly isn't declining either. The industry, meanwhile, is spending roughly a million dollars an hour advertising its products while fighting every government action to reduce smoking. The conversation turns to what actually works and what's being abandoned. King argues the two most effective interventions available are reducing nicotine levels in cigarettes and banning menthol, credits Congress for getting the Tobacco Control Act right, and stresses that Congress — not the FDA acting alone — has to be the one to regulate tobacco, which is precisely why sidelining the agency is so damaging. He and Chuck get into the questions nobody in Washington wants to answer: why are cigarettes legal at all, how are sugary alcoholic beverages not treated in the same category, and where did the money from the 1998 master settlement actually go. King is pointed that the MAHA movement, for all its rhetoric about chronic disease, has done nothing prominent on tobacco, and that the FDA is now actively undermining both the science and the law it was built to enforce. His closing warning is the bleakest note of the episode: America is in a public health apocalypse that will take decades to repair, it will be enormously hard to recruit a next generation into the field, the entire world will be harmed by the collapse of American public health infrastructure — and the impacts are only just beginning to show up. Finally, Chuck hops into the ToddCast Time Machine to revisit Watergate and Richard Nixon’s resignation, and answers listeners’ questions in the “Ask Chuck” segment. Play ball and swing for the fences on FanDuel, an official partner of the MLB at https://FANDUEL.COM. Protect your family with life insurance from Ethos. Get up to $3 million in coverage in as little as 10 minutes at https://ethos.com/chuck. Application times may vary. Rates may vary. For free and unbiased Medicare help, dial (980) 734-3985 to speak with my trusted partner, Chapter, or go to askchapter.org/chuck /*Paid Partnership Chapter and its affiliates are not connected with or endorsed by any government entity or the federal Medicare program. Chapter Advisory, LLC represents Medicare Advantage HMO, PPO, and PFFS organizations and stand alone prescription drug plans that have a Medicare contract. Enrollment depends on the plan’s contract renewal. While we have a database of every Medicare plan nationwide and can help you to search among all plans, we have contracts with many but not all plans. As a result, we do not offer every plan available in your area. Currently we represent 50 organizations which offer 18,160 products nationwide. We search and recommend all plans, even those we don’t directly offer. You can contact a licensed Chapter agent to find out the number of products available in your specific area. Please contact Medicare.gov, 1-800-Medicare, or your local State Health Insurance Program (SHIP) to get information on all of your options. Timeline: (Timestamps may vary based on advertisements) 00:00 Chuck Todd’s introduction 06:15 The Iran war has become a global conflict 06:45 Once again Trump issues threats, then walks them back 08:15 War is one of biggest strategic mistakes in decades 09:00 Increased gas prices have cost households additional $560 10:30 CISA warns that Iranian hackers are targeting water infrastructure 11:15 Iran could cause unreliability to the American water supply 13:00 Trump used hacking attacks to blame Minnesota Democrats 13:45 Trump didn’t blame the attacker, he blamed the victim 15:30 Jeanine Pirro blamed former Olympian for damage to reflecting pool 16:00 Dept. of Interior had documents proving otherwise, Pirro dropped case 17:00 Pirro presented false evidence to a grand jury 18:30 Trump publicly disagreed with Pirro dropping case, says it was vandals 19:30 Trump’s staff is shielding him from the truth 21:00 Trump’s lack of understanding reality is terrible for him 21:30 Trump’s low approval is a midterm disaster in the making 23:00 Stephanie Grisham says 85% of negative info is kept from Trump 24:15 People who bring Trump bad news don’t last very long 25:30 Republicans aren’t campaigning like things are going well 26:00 Ken Paxton puts out an affordability agenda, looks like a Dem proposal 27:15 Trump still saying affordability is scam made up by Democrats 28:15 Trump can’t understand the reality of the situation 28:45 Was Trump briefed on Iran hack… then attacked Minnesota anyway? 30:00 Trump’s first instinct was to find a Democrat to blame 30:45 Trump is demented with polarization disease 31:15 Trump cares more about his narrative than American citizens 32:15 Trump is bragging about his grifting an Americans are tired of it 33:15 Anti-Corruption is a massively effective midterm strategy 33:45 Chuck Schumer rolls out a stinker of an anti-corruption bill 34:45 WSJ publishes airtight piece about Trump’s overt corruption 35:45 There’s no buffer or plausible deniability for Trump in the corruption story 36:45 Trump is basically advertising that government is a pay to play scheme 37:45 There’s a list of presidential promises for favors that have been bought 38:15 Trump has raised $800m in pay for play schemes with little accounting 39:00 There is no law outlawing a president from raising unlimited money 39:30 Trump is now the biggest alligator in the swamp 40:15 Schumer’s bill is a piece of garbage, why many senators didn’t sign on 41:45 Jamie Raskin is performing oversight, Schumer wants agency to do it for him 42:30 The bill wouldn’t even cover the corruption outlined by the WSJ story 44:00 The bill is unconstitutional because it names individuals 45:00 Laws can target behavior, not individuals. It’d be thrown out in court 45:45 The agency Schumer proposed would live in the executive branch 46:15 Agency to stop a corrupt president would be staffed by the president?? 47:15 SCOTUS says president can fire the heads of exec branch agencies 48:45 If bill passed, Trump would pick agency head and 7 members of board 49:15 Congress can perform all the oversight the proposed agency would do 50:30 Congress could stop all this corruption if it wanted to 52:00 Schumer’s idea is to hand more power to the executive branch??? 54:30 The plan from congress is to write themselves out of oversight? 57:00 Schumer’s bill will never see the light of day 57:45 Michigan & Wisconsin will show where the Democratic party is headed 59:30 Abdul El-Sayed made clear his goal is to change the Democratic party 1:00:15 His campaign is a movement inside a senate race 1:01:00 Francesca Wong in Wisconsin is frontrunner & endorsed by DSA 1:01:45 Establishment hasn’t coordinated well to stop Wong 1:02:15 Movement politicians are usually right about the future, wrong about present 1:03:30 Sometimes the movement comes first, sometimes the coalition does 1:04:00 DSA has become a force, and is now calling for abolishing the senate 1:05:00 Senate democrats pushed back, but didn’t defend the senate 1:05:45 The senate is a feature, not a bug 1:06:30 The senate is a brake on political extremism 1:07:15 The response is to win the argument, not rewrite the rules 1:08:00 Movement nominees are easier to defeat than governing ones 1:14:15 Brian King (FDA center on tobacco) joins the Chuck ToddCast 1:18:00 We made incredible progress reducing cigarette smoking 1:18:30 Tobacco companies donated and received regulatory capture 1:19:15 Flavored vapes appeal more to kids & are problematic 1:20:45 Trump was pressured by executives from tobacco industry 1:21:30 There were multimillion dollar donations to Trump’s PAC 1:23:00 What’s the actual health data on nicotine outside of smoking? 1:23:30 Combustible products are the most harmful 1:24:00 Nicotine is highly addictive but isn’t causing the harm and deaths 1:24:45 Nicotine can harm the adolescent brain, it’s not risk free 1:25:30 Comparing nicotine vs. caffeine 1:27:15 Vaping typically isn’t a gateway back into smoking 1:28:30 There’s been pressure on FDA to bring back flavored products 1:31:00 $1M dollars an hour is being spent advertising tobacco products 1:31:45 Industry has been fighting all government action to reduce smoking 1:33:15 The FDA has been sidelined in the fight against smoking 1:33:45 Why are cigarettes even legal at all? 1:35:15 Tobacco farmers have transitioned to other crops in other countries 1:37:15 Reducing nicotine levels is highly effective 1:37:45 Outlawing menthol is also highly effective 1:39:30 Congress got it right with the Tobacco Control Act 1:41:15 How are sugary alcoholic beverages not in the same category? 1:42:15 What is age gating technology and how does it work? 1:44:15 Do we have good data on usage for people under 18? 1:46:45 Nicotine pouch usage isn’t high amongst kids, but isn’t going down 1:47:15 What is the data about health impacts from pouches? 1:48:45 Nicotine has a strong stimulant effect, helps with attention 1:49:30 Settlement in ‘98 required tobacco companies to pay costs in perpetuity 1:50:00 States have diverted those funds to other purposes 1:51:00 Did the tobacco industry actually take a hit from the settlement? 1:51:45 If still at FDA, what changes would you implement? 1:52:15 FDA has been undermining the science and the law 1:53:15 Effectiveness of banning indoor smoking 1:54:30 Should preventing underage addictions be the north star? 1:56:45 Congress has to regulate tobacco, FDA can’t do it on its own 1:57:30 MAHA hasn’t done anything prominent on tobacco 1:59:45 Is there litigation that could be pursued here? 2:01:00 We’re in a public health apocalypse, will take decades to repair 2:01:45 It will be hard to recruit people into public health 2:03:30 The entire world will be harmed by collapse of American public health 2:05:15 The impacts are just beginning to show up, will get worse 2:07:00 Toddcast Time Machine - The five days that ended Richard Nixon 2:07:30 Nixon resigned 52 years ago, this week 2:08:15 Why is Nixon the only president that paid a price for his corruption? 2:09:15 We tell the story of Watergate backwards and start with resignation 2:10:30 The June arrests weren’t the beginning of Watergate 2:12:15 We don’t know what Nixon’s operation learned before the arrests 2:14:00 We never got full answer on the missing 18 minutes 2:14:45 Supreme Court stayed in session during summer to oversee Watergate 2:15:15 Smoking gun tape goes public six days after the break-in 2:16:00 Nixon needed 34 votes in the senate to survive, only had 16 2:16:45 Impeachment in the house was a foregone conclusion 2:17:15 Senators didn’t demand he resign, just showed Nixon the numbers 2:20:30 How different would history have looked had Nixon survived? 2:21:15 Ask Chuck 2:21:30 Is presidency becoming more powerful in a way that could outlast Trump 2:24:30 Can the U.S. government create a true unbiased media source? 2:28:15 Would mandatory voting create better political participation? 2:32:45 Would Illinois make for a better early primary state? 2:34:30 Why not hold every primary on the same day? 2:36:45 Personal anecdote about AI job displacement and fearSee omnystudio.com/listener for privacy information.
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Recent weeks have been a whirlwind of activity in the pharmaceutical and biotech sectors, showcasing significant strides in scientific breakthroughs, regulatory advancements, and strategic industry maneuvers. Replimune's Vusolimogene Oderparepvec has emerged as a beacon of hope in the fight against advanced melanoma. This gene therapy, utilizing an oncolytic virus, has recently received a positive nod from an advisory committee for its Phase 1/2 trial. When combined with PD-1 checkpoint inhibitors, it holds promise for enhancing immune responses against tumors—a critical development in cancer treatment that may redefine therapeutic strategies. This advancement follows two prior FDA rejections, underscoring the multifaceted evaluation process drugs undergo before approval and demonstrating that perseverance can eventually lead to success. Meanwhile, AstraZeneca and Daiichi Sankyo have achieved a milestone with the European Union's approval of Datopotamab Deruxtecan for treating unresectable or metastatic triple-negative breast cancer (TNBC). As an antibody-drug conjugate targeting the Trop-2 protein, it offers new hope to TNBC patients who often have limited options. This approval underscores the potential of antibody-drug conjugates in oncology, supported by promising Phase 3 trial data. Regeneron Pharmaceuticals is enjoying notable revenue growth thanks to Dupixent, a monoclonal antibody addressing autoimmune and respiratory diseases. Such financial success underscores the expanding role of biologics in tackling chronic illnesses, reflecting a broader industry trend towards biologically-based treatments. In business news, Pharmanovia's licensing deal with Impact Therapeutics for Senaparib signifies strategic expansion in oncology therapeutics. Similarly, Kaigene's agreement with Taisho Pharmaceutical highlights ongoing interest in autoimmune therapies, illustrating how companies are leveraging partnerships to broaden their therapeutic horizons. Pfizer is on the brink of expanding its label for Ritlecitinib (Litfulo), a JAK3 inhibitor that showed positive results in Phase 3 trials for nonsegmental vitiligo. By targeting autoimmune pathways, this small molecule could offer new hope to vitiligo patients seeking effective treatments. Litfulo is advancing through regulatory stages following successful trials, poised to provide an oral alternative for non-segmental vitiligo—a potential game-changer that could improve patient compliance and expand treatment options beyond Incyte's Opzelura. However, not all news is positive. Novo Nordisk faced disappointment when its Ziltivekimab failed a Phase 3 trial for atherosclerotic cardiovascular disease with chronic kidney disease. Despite this setback, Novo Nordisk remains optimistic about ongoing trials Artemis and Hermes as potential lifelines for their CKD program. Success could diversify their portfolio and introduce novel therapeutic options for CKD patients. Additionally, financial hurdles surfaced as Daiichi Sankyo saw an 11% share drop due to an accounting error, and Alnylam Pharmaceuticals' market value took a hit following a lowered revenue forecast for its TTR drug. On a global scale, the Trump administration has allocated $600 million to GAVI for childhood immunizations worldwide. This funding reversal emphasizes ongoing efforts to ensure vaccine accessibility across the globe—an essential component of public health initiatives. The dynamic nature of these developments reflects both the potential and challenges within the pharmaceutical landscape. The promising avenues presented by gene therapy, antibody-drug conjugates, and JAK inhibitors are tempered by clinical setbacks and financial volatility, underscoring the rigorous demands faced by industry stakeholders. In other industry news, AbbVie's Skyrizi continues to thrive despite increasing competition in the psoriasis market. With sales reaching $5.55 billion in Q2 2026, Skyrizi demonstrates the sustained demand for innovative biologics that enhance treatment efficacy and safety profiles. Karyopharm Therapeutics remains committed to its XPO1 inhibitor Xpovio despite setbacks in other indications like endometrial cancer. Their focus on myelofibrosis illustrates a strategic pivot towards hematologic malignancies where unmet needs persist. Oral GLP-1 receptor agonists are gaining ground as Novo Nordisk's Wegovy pill and Eli Lilly's Foundayo vie for dominance in weight management solutions. These oral formulations promise increased accessibility over traditional injectables. Regulatory arenas continue to evolve with AbbVie's Rinvoq gaining European clearance for alopecia and vitiligo. Such approvals highlight regulatory bodies' critical role in expanding market access across diverse therapeutic areas. Strategic partnerships also abound as WellSpan Health collaborates with Hippocratic AI to integrate artificial intelligence into healthcare solutions—a growing trend aimed at enhancing clinical decision-making capabilities. Meanwhile, Apnimed's $192 million IPO success indicates strong investor confidence in novel therapeutics like its sleep apnea treatment—a reflection of biopharma's financing dynamics where targeted therapies draw significant interest. Overall, these updates paint a vivid picture of an industry characterized by relentless innovation through scientific research, strategic alliances, and regulatory progress—all aimed at improving patient outcomes amidst evolving market demands. The industry's focus on breakthrough technologies continues to shape global health initiatives by offering new opportunities for patient care across various conditions. As companies navigate this dynamic environment marked by both promise and challenge—their ability to innovate scientifically while engaging strategically with regulators will be crucial to bringing novel therapies effectively into clinical practice where they can make meaningful impacts on patients' lives worldwide.Support the show
Peptides are the latest craze in health and wellness, with advocates claiming they can boost recovery, build muscle, and extend longevity—even as critics raise safety concerns. Following a key FDA advisory panel vote on peptides, FOX News Correspondent Alex Hogan spoke with Wellness Expert and Keeping It Real podcast host Jillian Michaels on the FOX News Rundown about the trend, as well as the risks and benefits of the drugs. They explore the real science, the safety risks of imported supplements, and Jillian's firsthand experience with the trend. The conversation was too long for the midweek edition, so today on the FOX News Rundown: Extra, we bring you the full, unedited conversation with wellness expert Jillian Michaels-- and let you learn even more about peptides. Don't miss a single episode—follow The FOX News Rundown on your favorite podcast app today! Learn more about your ad choices. Visit podcastchoices.com/adchoices
Today, I want to tell you a story that sounds like it was completely made up for a movie script, but it's 100% real. Imagine an automotive mechanic in Argentina. He has zero medical training, no background in obstetrics, and no clinical degree. One night, he sees a simple party trick on YouTube: how to get a lost cork out of the inside of an empty wine bottle using nothing more than an inflated plastic bag. Most people would laugh, finish their glass of wine, and move on. But this mechanic, Jorge Odón, looked at that plastic bag and had a radical thought: Could this same basic physics principle be used to safely deliver a trapped baby during second-stage labor? Fast forward through years of engineering refinements, global partnerships, and early clinical pilots, and we get the Odón device- or OdonAssist™. It is, without a doubt, one of the most creative and innovative mechanical concepts to hit the field of operative vaginal delivery in generations. Instead of rigid metal blades applying direct compression, or high-pressure suction cups on the scalp, it uses an inflatable pneumatic cuff wrapped inside a lubricated, double-layered polyethylene sleeve. The inner layer grips the fetal vertex, while the outer layer glides smoothly against the vaginal walls, replacing high friction with plastic-on-plastic sliding action. But, and this is a big "but", as clinicians, we don't practice medicine based on good ideas or clever engineering alone. We practice based on rigorous, reproducible evidence on efficacy and safety. And that's where the narrative gets complicated. Although the device recently secured CE mark approval in Europe, it is not FDA approved in the United States. Why? Because despite nearly two decades of development, it is still facing a major shortage of large-scale Phase 3 comparative data (non-inferiority data). And the data it does have is not quite as impressive as its design would imply. Listen in for details. 1. Mottet N, et al. Safety and efficacy of the OdonAssist inflatable device for assisted vaginal birth: the BESANCON ASSIST study. American Journal of Obstetrics & Gynecology, 2023; 230, S947-S9582. Hotton EJ, Lenguerrand E, Wade J, et al. The OdonAssist inflatable device for assisted vaginal birth—the ASSIST II study (United Kingdom). Am J Obstet Gynecol. 2024;230(3S):S932-S946.e3.3. https://www.mnhi.com/odonassist (CE approval)4. ACOG PB 219; 2020.
Peptides are the latest craze in health and wellness, with advocates claiming they can boost recovery, build muscle, and extend longevity—even as critics raise safety concerns. Following a key FDA advisory panel vote on peptides, FOX News Correspondent Alex Hogan spoke with Wellness Expert and Keeping It Real podcast host Jillian Michaels on the FOX News Rundown about the trend, as well as the risks and benefits of the drugs. They explore the real science, the safety risks of imported supplements, and Jillian's firsthand experience with the trend. The conversation was too long for the midweek edition, so today on the FOX News Rundown: Extra, we bring you the full, unedited conversation with wellness expert Jillian Michaels-- and let you learn even more about peptides. Don't miss a single episode—follow The FOX News Rundown on your favorite podcast app today! Learn more about your ad choices. Visit podcastchoices.com/adchoices
Are your tampons quietly exposing you to toxic metals and chemicals that could affect your hormones and fertility? In this episode of Building Your Family, Dr. Nancy Reame breaks down what the FDA has (and hasn't) done on tampon safety since 2005 and how that compares to Europe. We cover the real story behind tampon safety, Toxic Shock Syndrome, and what the science actually says about toxins in period products. You'll learn how chemicals are absorbed through the vagina, what we know about toxic metals like lead and cadmium in tampons, and how all of this may impact menstrual health and fertility. Dr. Reame explains: The history of tampon safety and how Toxic Shock Syndrome changed regulations Why US tampon regulations haven't been updated since 2005, and how Europe handles toxic materials differently How and why the vagina is so absorbent, and what that means for chemical exposure What current research suggests about toxic metals and endocrine-disrupting chemicals in period products The real risks of long-term exposure vs what's been overhyped Pros and cons of alternatives like menstrual cups and pads (including how to use them safely) How to read labels, evaluate brands, and find reliable, science-based resources How to stay appropriately concerned without spiraling into panic We also talk about advocacy: how to push for better testing, transparency in ingredients, and stronger public health guidance for women's health products. If you care about menstrual health, fertility, and safer period products, hit subscribe, share this episode with a friend, and check the links in the description for the research and resources mentioned. PubMed: https://pubmed.ncbi.nlm.nih.gov/32382713/ Consumer reports: https://www.consumerreports.org/ Made Safe: https://madesafe.org/ Mamavation: https://mamavation.com/ #tamponsafety #toxicshocksyndrome #periodproducts #womenshealth #menstrualhealth #fertility #toxins #endocrinedisruptors #reproductivehealth #periodtalk #buildingyourfamilypodcast
Peptides are the latest craze in health and wellness, with advocates claiming they can boost recovery, build muscle, and extend longevity—even as critics raise safety concerns. Following a key FDA advisory panel vote on peptides, FOX News Correspondent Alex Hogan spoke with Wellness Expert and Keeping It Real podcast host Jillian Michaels on the FOX News Rundown about the trend, as well as the risks and benefits of the drugs. They explore the real science, the safety risks of imported supplements, and Jillian's firsthand experience with the trend. The conversation was too long for the midweek edition, so today on the FOX News Rundown: Extra, we bring you the full, unedited conversation with wellness expert Jillian Michaels-- and let you learn even more about peptides. Don't miss a single episode—follow The FOX News Rundown on your favorite podcast app today! Learn more about your ad choices. Visit podcastchoices.com/adchoices
Ali's guest today is Jess Mayhugh, a writer and editor who spent nearly a decade trying to have a baby before the arrival of her son, Cole. Jess's journey includes multiple miscarriages, rounds of IVF, several reproductive surgeries, and the unimaginable heartbreak of losing her newborn daughter, Lucy. On this episode, Jess opens up about navigating it all. It's a story of profound loss, incredible resilience, and massive love. IG: @jessmayhugh EPISODE SPONSORS: THE WORK OF ART BOOK SERIESAli's Children's Book Series about IVF, IUI and Family Building Through Assisted Reproductive Technology https://www.infertileafgroup.com/booksThe latest book in the Work of ART series, “You Are a Work of ART," is for every kiddo born through ART -- and the people who love them.Stay tuned for Petri Dish Princess, book #4, coming this fall!EXTEND FERTILITYExtend Fertility is a leading fertility clinic helping people take control of their reproductive futures through egg freezing, embryo freezing, IVF, and more. With a focus on making fertility care more accessible, empowering, and personalized, Extend combines cutting-edge science with compassionate care to help patients understand their options and make informed decisions about if, when, and how they want to build a family.For more, go to extendfertility.comPHERDALIG: @pherdal_sciencePherDal is the world's first and only FDA-cleared, sterile, at-home insemination kit designed to help people build their families in the comfort of home. Created by parents who've been there, PherDal is safe, simple, and affordable—putting more options in your hands as you grow your family. Explore at PherDal.com.Go to PherDal.com today and use code INFERTILEAF for $10 off.Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy
On this episode, Jared and Jen introduce a new Full Moon Parasite Cleanse Protocol designed in conjunction with Cellcore Biosciences, to make parasite cleansing simpler, more affordable, and easier to follow than a comprehensive 90-day program. They explain why timing a cleanse around the full moon matters, discuss the role parasites may play in common symptoms like fatigue, bloating, brain fog, cravings, and digestive discomfort, and walk through each phase of the protocol - from drainage support and binders to rebuilding the gut afterward. They also compare this protocol to their original 90-day parasite cleanse, discuss who may benefit from each approach, and share practical tips for minimizing discomfort during a cleanse. They also explain the included symptom quiz, companion eBook, and how to choose the approach that best fits your health goals.Products:Full Moon Parasite Cleansing Protocols3 Month Parasite Cleansing ProtocolCellCore CoreMend GI Constipation Support Additional Information:Parasite Burden Quiz359: Comprehensive Detoxification of Parasites, Lyme, and Other Toxins With Dr. Todd Watts of CellCore Biosciences431: Are Parasites Part of Your Health Concerns? With Dr. Jay Davidson432: Your Parasite Cleansing User's Guide455: Real World Results From a Parasite Cleanse536: CellCore ParaKit Explained: How Each Product Supports Parasite Cleansing543: How to Choose the Right Binder for Detox, Parasites, Mold, and Metals653: Laxatives Blow! Constipation, Gut Health & the Real Path to Regularity657: The Leaky Gut Protocol: A Research-Based Plan to Restore Gut HealthVisit the podcast website here: VitalityRadio.comYou can follow @vitalitynutritionbountiful and @vitalityradio on Instagram, or Vitality Radio and Vitality Nutrition on Facebook. Join us also in the Vitality Radio Podcast Listener Community on Facebook. Shop the products that Jared mentions at vitalitynutrition.com. Let us know your thoughts about this episode using the hashtag #vitalityradio and please rate and review us on Apple Podcasts. Thank you!Just a reminder that this podcast is for educational purposes only. The FDA has not evaluated the podcast. The information is not intended to diagnose, treat, cure, or prevent any disease. The advice given is not intended to replace the advice of your medical professional.This podcast is produced by DrTalks.comhttps://drtalks.com/podcast-service/
In his weekly clinical update, Daniel Griffin and Vincent Racaniello discuss the numerous attempts by states to roll back vaccine laws, the recent surge of Dengue virus cases in Sri Lanka, the national cyclospora outbreak, new screwworm and Legionnaires cases, launching of the CHaT-Ox Ebola vaccine trail, scale of the Ebola outbreak in the Congo and if cross-reactive Ebola antibodies are effective, before Dr. Griffin deep dives into the measles outbreak including the new Pennsylvania dashboard, recent statistics RSV, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, Johns Hopkins measles tracker, how to access and pay for Paxlovid, where to go for answers about long COVID-19, how long COVID and ME/CFS differ and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Dozens of States Tried to Roll Back Vaccine Laws. Here's How They Fared. (NY Times) Dengue cases in Sri Lanka surge past 80,000 (Newswire) After withdrawing false-positive test, FDA says Taylor Farms lettuce still a focus of Cyclospora investigation (CIDRAP) A difficult-to-trace parasite, messaging missteps contribute to summer of overwhelming Cyclospora outbreaks (CIDRAP) Surveillanceof Cyclosporiasis (CDC: Cyclosporiasis) Infectious DiseaseOutbreaks (Michigan: Health & Human Services) Cyclosporiasis Cases in North Carolina (North Carolina: Division of Public Health) Cyclospora Infection (Cyclosporiasis) (NYC Health) Legionnaires' Disease (NYC Health) MAP UPDATE: 50 buildings in Manhattan outbreak zone test positive for live bacteria (NBC: News) Dashboard SCREWWORM.Gov (USDA: Animal and Plant Health Inspection Service) CDC Activates Emergency Operations Center for New World Screwworm Response (CDC Newroom) Ebola dashboard (ebola.fyi) EBOLA:The Democratic Republic of the Congo, 2026 (WHO) Bundibugyo virus disease outbreak Democratic Republic of the Congo (WHO: Democratic Republic of Congo) Ebola Outbreak: Current Situation (CDC:Ebola) First volunteer vaccinated in the world's first Bundibugyo ebolavirus vaccine trial (University of Oxford) Cross-Reactive Bundibugyo Antibody Responses after Receipt of Licensed Ebola Vaccines (NEJM) Wastewater for measles (WasterWater Scan) Measles cases and outbreaks (CDC Rubeola) Big outbreak, bright lights…Measles Dashboard (South Carolina Department of Public Health) Utah measles outbreak response (Utah Department of Health and Human Services) UtahMeasles Dashboard (Utah Department of Health and Human Services) Measles (VDH: Virginia Department of Health) Tracking Measles Cases in the U.S. (Johns Hopkins) HAP's Latest News Pa. Launches New Measles Dashboard (Hospital + HealthSystem Association of Pennsylvania) Measles vaccine recommendations from NYP (jpg) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts (ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) USrespiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) Flu vaccine recommendations: Vaccines and Related Biological Products Advisory Committee March 12, 2026 Meeting Announcement (FDA) WHO updates all 3 viral strains to be included in fall flu shots (CIDRAP) FDA vaccine advisers recommend adding subclade K to fall shots (CIDRAP) Weekly surveillance report: cliff notes (CDC FluView) OPTION 2: XOFLUZA $50 Cash Pay Option (xofluza) RSV: Waste water scan for 11 pathogens (WastewaterSCan) Respiratory Diseases (Yale School of Public Health) USrespiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Vaccines for Adults (CDC: Respiratory Syncytial Virus Infection (RSV)) Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP) Respiratory Diseases (Yale School of Public Health) Impact of Nirsevimab in Its Second Season on Respiratory Syncytial Virus and Non-RSV Admissions in Children Under 5 (Pediatric Infectious Disease Journal) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Where to get pemgarda (Pemgarda) EUAfor the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Help your eligible patients access PAXLOVID with the PAXCESS Patient Support Program (Pfizer Pro) Understanding Coverage Options (PAXCESS) Remdesivir and All-Cause Graft Loss Among Kidney Transplant Recipients With Symptomatic COVID-19 (JAMA: Network Open) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Anticoagulationguidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) Skeletal muscle properties in long COVID and ME/CFS differ from those induced by bed rest (Nature Communications) Loss of vesicular monoamine transporter 2 in striatum of long COVID and relationship to neuropsychiatric symptoms (eBioMedicine) The answers: Long COVID Reaching out to US house representative Letters read on TWiV 1344 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.
>p>Broadcast from KSQD, Santa Cruz on 7-30-2026: A type of coffee brewed from beans that have been altered by passage through the digestive track of civet cats is a delicacy in Southeast Asia. A Scientific Reports paper using gas chromatography analyzed Kopi Luwak (civet-processed coffee beans) versus fresh-picked beans, finding elevated caprylic and capric acids that carry the characteristic flavor notes found in dairy products. Dr. Manuel Esteller sampled and tested the blood, saliva, urine, and stool of the oldest human Maria Branyas Morera, who died last year at 117. Despite exceptionally short telomeres, she carried anti-inflammatory genetic variants seen in long-lived dogs, worms, and flies, and had unusually high Bifidobacterium levels—likely boosted by her three-daily-servings-of-yogurt habit. Dr. Dawn defends sunscreen use against Environmental Working Group scare campaigns, noting that concerns about absorption of sunscreen ingredients into blood remain theoretical while sunburn's melanoma link is well-established. She argues that a badly sunburned toddler starts a clock that can produce melanoma by the late teens. The FDA advisory committee is reviewing certain short amino acid chains popularly known as "peptides" for potential compounding-pharmacy production, covering proposed to treat ulcerative colitis, wound healing, insomnia, insulin resistance, migraines, and osteoporosis. Dr. Dawn flags that five to seven committee members have industry conflicts of interest, but argues that even flawed approval is preferable to the current gray market, where analysis shows vials contain only 4-28% of labeled content along with endotoxin and toluene contamination. She proposes surveillance tracking of prescribed peptides to catch adverse effects early, citing a foreign melanocortin nasal spray tanning product that caused rare nasal melanomas as a cautionary example. Utah State biochemists working with the Cas12a2 CRISPR enzyme discovered that instead of behaving as a precise gene-editor like Cas9, it goes into an indiscriminate DNA-shredding mode after recognizing its target RNA. By programming it to recognize RNA sequences uniquely activated in cancer cells (embryonic-development genes that shouldn't be running in adults), researchers destroyed only the cancer cells in tissue culture, potentially offering a way to eliminate small metastases without healthy tissue toxicity. Cancer patients who received a COVID-19 mRNA vaccine within 100 days of starting immune checkpoint inhibitor therapy showed dramatically improved outcomes, with median survival in advanced lung cancer rising from 20 to 37 months. Non-mRNA vaccines (flu, pneumonia) showed no such benefit. Lab work suggests the mRNA triggers type-1 interferon release that activates tumor-infiltrating immune cells and drives them to lymph nodes to train other immune cells against the tumor. Researchers redesigned a CD40 agonist antibody to bind multiple receptors simultaneously by clustering with a second antibody, stretching the cell surface and triggering a powerful immune response. In a 12-patient trial, injecting one tumor caused all tumors to shrink in six patients and produced complete remission in two—including a melanoma patient with dozens of leg tumors and a metastatic breast cancer patient whose lung and liver tumors resolved after skin injection. Two small trials of CAR natural killer cells—engineered like CAR T-cells but derived from donor umbilical cord blood and thus potentially available off-the-shelf—showed remarkable results in autoimmune disease. All 27 systemic lupus patients targeting the CD19 protein on autoantibody-producing cells showed improvement, with some remaining in remission at nearly two years. A single Shanghai patient with systemic sclerosis showed restoration of normal skin and blood vessel structure. A paradox has emerged in advanced prostate cancer: while blocking testosterone halts early tumor growth, cancer cells eventually adapt to low-androgen conditions such that flooding tissues with testosterone in advanced disease can actually halt tumor progression by triggering cellular redifferentiation. Separately, Dr. Dawn reviews conflicting evidence on Parkinson's risk from androgen deprivation therapy, singling out enzalutamide (Xtandi) as the most concerning drug due to blood-brain barrier penetration, and recommending darolutamide as the safest alternative with matching prostate efficacy but minimal CNS entry.
Send us Fan MailA father's death from pancreatic cancer sparks a decades-long hunt for a better answer, and it leads to one surprising place: the cell walls of baker's yeast. We're joined by Mike Catto, a researcher and biotech founder, to unpack beta-glucan and why the specific 1-3/1-6 linkage he works with matters for immune modulation and cancer immunotherapy.We walk through Mike's path from early biopolymer work to acquiring failed injectable beta-glucan patents, rebuilding the process, and pushing through an expensive FDA clinical-trial journey. He shares why major cancer centres tested this approach, how a therapy can be labelled “fast-tracked” yet still stay out of patients' hands, and what he believes keeps an injectable option stuck in limbo.Then we slow down and get practical. Mike explains the proposed mechanism of action: priming innate immunity, including NK cells, so the immune system can better recognise and attack tumour targets. We also discuss oral versus injectable beta-glucan, daily immune support dosing, the idea of trained immunity, and the add-on protocol he uses for late-stage cancer cases, including ivermectin, fenbendazole, vitamin E, curcumin, and CBD oil tincture depending on the situation. Finally, we cover where he tells people to get the 1-3/1-6 beta-glucan product and what to avoid when shopping.If this conversation raises new questions for you about cancer treatment, immune support supplements, and the realities of drug approval, share it with someone who needs hope and options, then subscribe and leave a review so more people can find the show.Support the showhttps://www.jacksonfamilyministry.comhttps://bobslone.com/home/podcast-production/
President Donald Trump is defending the controversial Department of Justice "anti-weaponization fund" as his pick for permanent Attorney General hangs in the balance. An estimated 60,000 migrants rush the border between Morocco and Spain. New York becomes the latest state to take the prediction market Kalshi to court. Anthropic admits its AI models also went rogue and hacked outside systems. And certain peptides get one step closer to FDA approval. Learn more about your ad choices. Visit podcastchoices.com/adchoices
Wendy Strgar, recently named to the 2025 Forbes 50 Over 50 Innovation List, is an award-winning entrepreneur and the founder of Good Clean Love and Vaginal Biome Science. She pioneered BioMatched® technology, applying biomimicry to develop safer, science-based products that support vaginal health. As both CIO and CEO, Wendy has led groundbreaking research on the vaginal microbiome and helped influence FDA standards—making her a true innovator in women's health. In this episode, Wendy Stregar of Good Clean Love breaks down the science of the vaginal microbiome, exposing common product ingredients that harm it and sharing how her new telehealth platform, biomimicry-based products, and vaginal estradiol insights help women fix chronic BV, yeast infections, and painful sex. RESOURCES: Learn more about Wendy Strgar here: https://www.wendystrgar.com/ Instagram: @wendy.strgar @goodcleanlove Get 10% off Peluva minimalist shoe with coupon code COACHTARA here: http://peluva.com/coachtara CHAPTERS: 0:00 – Meet Wendy Strgar 2:27 – Sponsor: Peluva Shoes ad 4:15 – Gut, oral, and vaginal microbiome basics 8:56 – Women's health's 5% research problem 10:17 – Funding Vaginal Biome Science and misdiagnosis 12:47 – The K-Y/Astroglide propylene glycol problem 14:51 – pH, odor, and healthy bacteria basics 17:32 – Launching Good Clean Clinical Care 19:57 – Vaginal estradiol and why the carrier matters 22:23 – Telemedicine platform and doctor access 26:50 – Good Clean Love at Target, Walmart, and the Reset 28:44 – Crispatus and racial disparities in birth outcomes 33:04 – Cancer treatment and vaginal health 36:24 – Clitoral anatomy and nerve endings 40:14 – The three-step biomimicry method 49:16 – Higher Coaching, app, and retreats 54:23 – Breaking the recurring BV, yeast, and UTI cycle 1:02:21 – Probiotics, cost, and the orgasm gap 1:04:02 – Orgasm science, scent, and arousal WORK WITH TARA: Are You Looking for Help on Your Wellness Journey? Here's how Tara can help you: TRY TARA'S APP FOR FREE: http://taragarrison.com/app INDIVIDUAL ONLINE COACHING: https://www.taragarrison.com/work-with-me CHECK OUT HIGHER RETREATS: https://www.taragarrison.com/retreats SOCIAL MEDIA: Instagram @coachtaragarrison TikTok @coachtaragarrison Facebook @coachtaragarrison Pinterest @coachtaragarrison INSIDE OUT HEALTH PODCAST SPECIAL OFFERS: ☑️ Upgraded Formulas Hair Test Kit Special Offer: https://bit.ly/3YdMn4Z ☑️ Upgraded Formulas - Get 15% OFF Everything with Coupon Code INSIDEOUT15: https://upgradedformulas.com/INSIDEOUT15 ☑️ Rep Provisions: Vote for the future of food with your dollar! And enjoy a 15% discount while you're at it with Coupon Code COACHTARA: https://bit.ly/3dD4ZSv If you loved this episode, please leave a review! Here's how to do it on Apple Podcasts: Go to Inside Out Health Podcast page: https://podcasts.apple.com/us/podcast/inside-out-health-with-coach-tara-garrison/id1468368093 Scroll down to the 'Ratings & Reviews' section. Tap 'Write a Review' (you may be prompted to log in with your Apple ID). Thank you!
Tarabuster Thursday with Tara Devlin. July 30, 2026
Send Zorba a message!Zorba shares his thoughts on the recent Cyclosporiasis outbreak, and how staffing cuts implemented by The Department of Government Efficiency (DOGE) have made the outbreak worse.Support the showProduction, edit, and music by Karl ChristensonSend your question to Dr. Zorba (he loves to help!):Phone: 608-492-9292 (call anytime)Email: askdoctorzorba@gmail.comWeb: www.doctorzorba.orgStay well!
This week, Emily Bazelon, John Dickerson, and David Plotz discuss the expanding Iran war and what it means for Trump that news of U.S. missile shortages is leaking from the inside, the blend of conspiracy theory and Rand Paul's personal umbrage that drove the show trial of a Senate hearing with Dr. Anthony Fauci, and various developments that brought medication abortion and FDA restrictions back to the news this week.Here are this week's chatters: Emily: Julia Lurie for Mother Jones: Me, Myself, and IUDs John: Space Daily: Astronauts returning from six-month missions describe a persistent 'observer' sensation — the feeling of watching their own lives from a half-step outside the frame, weeks after they're back on the ground David: Jill Lawless for The Associated Press: Glen Hansard, Irish musician who won Oscar for ‘Once,' dies in motorcycle crash; Once (2007) Trailer HD | Glen Hansard | Markéta Irglová (YouTube); RTÉ News on YouTube: 'Fairytale of New York' played at Shane MacGowan's funeral; City Cast: Your City Could Be Better (podcast); Eli Sabin for New Haven Listener chatter from Craig Kujawa in Washington, D.C.: Barbershop Harmony Society: History Made: GQ Wins World Championship; Barbershop Harmony Society: GQ - Mothers & Daughters (Maddie Zahm cover) • 2026 BHS International Quartet Champions (YouTube) For this week's Slate Plus bonus episode, Emily, John, and David discuss the rise of the Democratic Socialists of America with guest Grace Mausser, Co-Chair of the New York City DSA. They talk about its European-style organizing model, its uneasy alliance with the Democratic Party, the primacy of canvassing and volunteering, and the art of compromise. In the latest Gabfest Reads, John Dickerson interviews Maggie Haberman and Jonathan Swan about their new book Regime Change: Inside the Imperial Presidency of Donald Trump. Drawing on extensive reporting from inside the White House, they explore how Trump's second term differs radically from his first, from his decision-making process to the people surrounding him and his relationship with power, money, and the presidency itself. Email your chatters, questions, and comments to gabfest@slate.com. (Messages may be referenced by name unless the writer stipulates otherwise.) Podcast production by Nina Porzucki Research by Emily DittoYou can find the full Political Gabfest show pages here. Want more Political Gabfest? Join Slate Plus to unlock weekly bonus episodes. Plus, you'll access ad-free listening across all your favorite Slate podcasts. You can subscribe directly from the Political Gabfest show page on Apple Podcasts and Spotify. Or visit slate.com/gabfestplus to get access wherever you listen. Find out more about David Plotz's monthly tours of Ft. DeRussy, the secret Civil War fort hidden in Rock Creek Park. Follow@SlateGabfest on X / https://twitter.com/SlateGabfestSlate Political Gabfest on Facebook / https://www.facebook.com/Gabfest/Need to set up your Slate Plus feed? If you subscribed through Slate.com, check out our FAQ at slate.com/podcastfaqs for easy instructions. Members subscribed via Apple Podcasts get automatic access—no setup required. Hosted on Acast. See acast.com/privacy for more information.
On the heels of the success of GLP-1s like Ozempic, other peptide treatments are flooding the marketplace—and advertising spaces. But even as the Trump administration's FDA discusses approving more treatments and the businesses selling them proliferate, many peptides are sitting in a legal and medical gray area. So how real - and safe - is this peptide hype?Guest: Kate Knibbs, senior writer at WIRED.Want more What Next? Subscribe to Slate Plus to access ad-free listening to the whole What Next family and across all your favorite Slate podcasts. Subscribe today on Apple Podcasts by clicking “Try Free” at the top of our show page. Sign up now at slate.com/whatnextplus to get access wherever you listen.Podcast production by Rob Gunther, Evan Campbell, Madeline Thames-Ducharme and Patrick Fort.Paige Osburn is the senior supervising producer of What Next and What Next TBD. Hosted on Acast. See acast.com/privacy for more information.
This week, Emily Bazelon, John Dickerson, and David Plotz discuss the expanding Iran war and what it means for Trump that news of U.S. missile shortages is leaking from the inside, the blend of conspiracy theory and Rand Paul's personal umbrage that drove the show trial of a Senate hearing with Dr. Anthony Fauci, and various developments that brought medication abortion and FDA restrictions back to the news this week.Here are this week's chatters: Emily: Julia Lurie for Mother Jones: Me, Myself, and IUDs John: Space Daily: Astronauts returning from six-month missions describe a persistent 'observer' sensation — the feeling of watching their own lives from a half-step outside the frame, weeks after they're back on the ground David: Jill Lawless for The Associated Press: Glen Hansard, Irish musician who won Oscar for ‘Once,' dies in motorcycle crash; Once (2007) Trailer HD | Glen Hansard | Markéta Irglová (YouTube); RTÉ News on YouTube: 'Fairytale of New York' played at Shane MacGowan's funeral; City Cast: Your City Could Be Better (podcast); Eli Sabin for New Haven Listener chatter from Craig Kujawa in Washington, D.C.: Barbershop Harmony Society: History Made: GQ Wins World Championship; Barbershop Harmony Society: GQ - Mothers & Daughters (Maddie Zahm cover) • 2026 BHS International Quartet Champions (YouTube) For this week's Slate Plus bonus episode, Emily, John, and David discuss the rise of the Democratic Socialists of America with guest Grace Mausser, Co-Chair of the New York City DSA. They talk about its European-style organizing model, its uneasy alliance with the Democratic Party, the primacy of canvassing and volunteering, and the art of compromise. In the latest Gabfest Reads, John Dickerson interviews Maggie Haberman and Jonathan Swan about their new book Regime Change: Inside the Imperial Presidency of Donald Trump. Drawing on extensive reporting from inside the White House, they explore how Trump's second term differs radically from his first, from his decision-making process to the people surrounding him and his relationship with power, money, and the presidency itself. Email your chatters, questions, and comments to gabfest@slate.com. (Messages may be referenced by name unless the writer stipulates otherwise.) Podcast production by Nina Porzucki Research by Emily DittoYou can find the full Political Gabfest show pages here. Want more Political Gabfest? Join Slate Plus to unlock weekly bonus episodes. Plus, you'll access ad-free listening across all your favorite Slate podcasts. You can subscribe directly from the Political Gabfest show page on Apple Podcasts and Spotify. Or visit slate.com/gabfestplus to get access wherever you listen. Find out more about David Plotz's monthly tours of Ft. DeRussy, the secret Civil War fort hidden in Rock Creek Park. Follow@SlateGabfest on X / https://twitter.com/SlateGabfestSlate Political Gabfest on Facebook / https://www.facebook.com/Gabfest/ Hosted on Acast. See acast.com/privacy for more information.
Tickets for our live show in New York are on sale now! Get yours here. Peptides are a huge part of the wellness craze that's sweeping social media. Demand for restricted peptides has fueled an online gray market for injections promising youth, beauty and strength. Businesses are racing—and taking risks—to get in on the craze. WSJ's Sara Ashley O'Brien explores the burgeoning peptide market and how a recent FDA hearing could signal things are only just getting started. Jessica Mendoza hosts. Further Listening: - Trillion Dollar Shot - The FDA Boss on the Agency's MAHA Makeover Sign up for WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices
On the heels of the success of GLP-1s like Ozempic, other peptide treatments are flooding the marketplace—and advertising spaces. But even as the Trump administration's FDA discusses approving more treatments and the businesses selling them proliferate, many peptides are sitting in a legal and medical gray area. So how real - and safe - is this peptide hype?Guest: Kate Knibbs, senior writer at WIRED.Want more What Next? Subscribe to Slate Plus to access ad-free listening to the whole What Next family and across all your favorite Slate podcasts. Subscribe today on Apple Podcasts by clicking “Try Free” at the top of our show page. Sign up now at slate.com/whatnextplus to get access wherever you listen.Podcast production by Rob Gunther, Evan Campbell, Madeline Thames-Ducharme and Patrick Fort.Paige Osburn is the senior supervising producer of What Next and What Next TBD. Hosted on Acast. See acast.com/privacy for more information.
This week, Jasmin and Mariann dig into a wave of encouraging news for the plant-based movement alongside a sobering look at threats to wildlife protections. They cover new data showing plant-based sales climbing across Europe as prices and taste improve, the FDA’s struggle to define “ultra-processed foods” (and its decision not to ban them), a lawsuit challenging the Trump administration’s rollback…
Over 500 published papers stand behind one of the internet's most popular peptides, but fewer than 30 of the humans studied are in them. Dr. Gabrielle Lyon separates the molecule from the marketplace so you can tell real evidence from good marketing.In this solo episode, Dr. Gabrielle Lyon discusses:Why BPC-157's "mountain of evidence" collapses to a 99.7% animal-to-human ratio - 544 papers, but fewer than 30 humans across three uncontrolled pilot trialsHow to place any peptide on the spectrum from FDA-approved (GLP-1s like semaglutide) to investigational to compounded, and why "GLP-1s work, so peptides work" is a trapWhat the FDA quietly did in April 2026, and why removing a dozen peptides from its safety-concern list was driven by policy pressure, not new safety dataThe 4 questions to run on any peptide before you inject level of evidence, what the study measured, where it's sourced from, and whether it's banned in tested sportWhy the "boring work", resistance training, protein-anchored nutrition, and real recovery beat almost anything in a vialIf something is going into your body through a needle, the standard has to be higher than three words on a label that say "research use only." This episode gives you the framework to protect yourself before spending a dollar or taking a shot.Thank you to our sponsors:Head to https://bit.ly/4ftfObn and use code DRLYON for 25% off sitewide. That is K-E-T-T-L-E and Fire dot com slash DRLYON, code DRLYON for 25% off. Also available at select Sprouts, Whole Foods, and Kroger locations nationwide.BodyHealth - Use the code LYON20 to get 20% off your first order https://bit.ly/4vZs75j OneSkin - Get 15% off at https://bit.ly/44XXQYy with code DRLYONExplore More from Dr. Gabrielle LyonPremium Podcast Subscription: Ad-free episodes, key takeaway summaries, exclusive Q&A, and behind-the-scenes content https://foreverstrong.supercast.comWeekly newsletter: Recipes, podcast updates, and practical weekly insights https://drgabriellelyon.com/sign-up/Apply to become a patient: Personalized care with Dr. Lyon's clinical team https://drgabriellelyon.com/new-patient-inquiry/Connect with Dr. Gabrielle Lyon:Instagram: https://www.instagram.com/drgabriellelyon/TikTok: https://www.tiktok.com/@drgabriellelyon X (Twitter): https://x.com/drgabriellelyonFacebook: https://www.facebook.com/doctorgabriellelyon Chapters00:00 - Introduction01:30 - What a peptide is03:40 - The first mistake: treating peptides as one category05:50 - GLP-1s and the "peptides work" fallacy09:30 - FDA-approved peptides: tesamorelin and s15:40 - Repair peptides: BPC-157 and the Wolverine stack16:30 - 544 studies, 30 humans: the evidence gap20:00 - The strongest case for peptides25:30 - The strongest case against peptides29:00 - Compounded peptides and contamination risk30:00 - What the FDA quietly did in April 202633:40 - The 4 questions to ask before any peptide37:40 - The boring work that changes your life If you found this episode valuable, share it with someone who would benefit from it.Disclaimers: This episode includes paid sponsorships. The Dr. Gabrielle Lyon Podcast and YouTube are for general information purposes only and do not constitute the practice of medicine, nursing, or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast, YouTube, or materials linked from this podcast or YouTube is at the user's own risk. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they may have and should seek the assistance of their health care professional for any such conditions.
This week, Emily Bazelon, John Dickerson, and David Plotz discuss the expanding Iran war and what it means for Trump that news of U.S. missile shortages is leaking from the inside, the blend of conspiracy theory and Rand Paul's personal umbrage that drove the show trial of a Senate hearing with Dr. Anthony Fauci, and various developments that brought medication abortion and FDA restrictions back to the news this week.Here are this week's chatters: Emily: Julia Lurie for Mother Jones: Me, Myself, and IUDs John: Space Daily: Astronauts returning from six-month missions describe a persistent 'observer' sensation — the feeling of watching their own lives from a half-step outside the frame, weeks after they're back on the ground David: Jill Lawless for The Associated Press: Glen Hansard, Irish musician who won Oscar for ‘Once,' dies in motorcycle crash; Once (2007) Trailer HD | Glen Hansard | Markéta Irglová (YouTube); RTÉ News on YouTube: 'Fairytale of New York' played at Shane MacGowan's funeral; City Cast: Your City Could Be Better (podcast); Eli Sabin for New Haven Listener chatter from Craig Kujawa in Washington, D.C.: Barbershop Harmony Society: History Made: GQ Wins World Championship; Barbershop Harmony Society: GQ - Mothers & Daughters (Maddie Zahm cover) • 2026 BHS International Quartet Champions (YouTube) For this week's Slate Plus bonus episode, Emily, John, and David discuss the rise of the Democratic Socialists of America with guest Grace Mausser, Co-Chair of the New York City DSA. They talk about its European-style organizing model, its uneasy alliance with the Democratic Party, the primacy of canvassing and volunteering, and the art of compromise. In the latest Gabfest Reads, John Dickerson interviews Maggie Haberman and Jonathan Swan about their new book Regime Change: Inside the Imperial Presidency of Donald Trump. Drawing on extensive reporting from inside the White House, they explore how Trump's second term differs radically from his first, from his decision-making process to the people surrounding him and his relationship with power, money, and the presidency itself. Email your chatters, questions, and comments to gabfest@slate.com. (Messages may be referenced by name unless the writer stipulates otherwise.) Podcast production by Nina Porzucki Research by Emily DittoYou can find the full Political Gabfest show pages here. Want more Political Gabfest? Join Slate Plus to unlock weekly bonus episodes. Plus, you'll access ad-free listening across all your favorite Slate podcasts. You can subscribe directly from the Political Gabfest show page on Apple Podcasts and Spotify. Or visit slate.com/gabfestplus to get access wherever you listen. Find out more about David Plotz's monthly tours of Ft. DeRussy, the secret Civil War fort hidden in Rock Creek Park. Follow@SlateGabfest on X / https://twitter.com/SlateGabfestSlate Political Gabfest on Facebook / https://www.facebook.com/Gabfest/ Hosted on Acast. See acast.com/privacy for more information.
On the heels of the success of GLP-1s like Ozempic, other peptide treatments are flooding the marketplace—and advertising spaces. But even as the Trump administration's FDA discusses approving more treatments and the businesses selling them proliferate, many peptides are sitting in a legal and medical gray area. So how real - and safe - is this peptide hype?Guest: Kate Knibbs, senior writer at WIRED.Want more What Next? Subscribe to Slate Plus to access ad-free listening to the whole What Next family and across all your favorite Slate podcasts. Subscribe today on Apple Podcasts by clicking “Try Free” at the top of our show page. Sign up now at slate.com/whatnextplus to get access wherever you listen.Podcast production by Rob Gunther, Evan Campbell, Madeline Thames-Ducharme and Patrick Fort.Paige Osburn is the senior supervising producer of What Next and What Next TBD. Hosted on Acast. See acast.com/privacy for more information.
#AD This episode is sponsored by Daré Bioscience. DARE to PLAY™ Sildenafil Cream is a compounded drug. It is not FDA-approved. This product has not been reviewed by FDA for safety or efficacy. It is manufactured in a 503B outsourcing facility under pharmaceutical Good Manufacturing Practices (GMP). Shan sits down with four women to talk about the low libido nobody prepares you for: the 26-year-old who kept saying "I'm supposed to be in my prime" and quietly decided she was broken, the married woman delighting in her season of stillness, and Shan's own reframe that low libido is only a dysfunction if it comes with an F word (frustrating). Then Sabrina Martucci Johnson, founder and CEO of Daré Bioscience, explains what actually happens in the body when desire and arousal stop cooperating, and why women were told for almost 30 years it was all in their heads. Follow Sabrina Martucci Johnson LinkedIn: https://www.linkedin.com/in/sabrina-martucci-johnson/ TikTok: https://www.tiktok.com/@sabrinadareceo Follow Daré Bioscience LinkedIn: https://www.linkedin.com/company/dare-bioscience Instagram: https://www.instagram.com/darebioscience/ —- Learn more about DARE to PLAY™ https://daretoplaybio.com/ Unlock deeper pleasure with a roadmap designed for you — all it takes is 5 minutes. Go to https://beduc.at/bg2631-boody to learn more! Follow Indigo MateoInstagram: https://www.instagram.com/indigomateoMusic: http://www.indigomateo.com/ Follow Jamille McClendonInstagram: https://www.instagram.com/thahealingfactor Follow Saraijah BarnesInstagram: https://www.instagram.com/Rai.destinei Follow Brittany Johnsonhttp://instagram.com/brittbekountry Want more LOVERS? Follow Shan on Instagram → http://instagram.com/shanboodram Get a free Love Letter from Shan → http://loversbyshan.com/newsletter Join the LOVERS Community → https://www.loversbyshan.com/community Explore free quizzes + worksheets → http://loversbyshan.com/quizzes Learn more about your ad choices. Visit megaphone.fm/adchoices
An FDA panel has recommended allowing compounding pharmacies to make six unapproved peptides. Dr. Sanjay Gupta and CNN Health's John Bonifield discuss their popularity, safety concerns and what comes next. This episode was produced by Madeleine Thompson and Leying Tang. Medical Writer: Andrea Kane Showrunner: Dan Bloom Technical Director: Dan Dzula Sr. Director of Podcasts: Zach Goldbaum Learn more about your ad choices. Visit podcastchoices.com/adchoices
© 2020-2026 Ivy Podcast Discovery LLC
